

# I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease



Laurent Peyrin-Biroulet,<sup>1</sup> Jean-François Rahier,<sup>2</sup> Julien Kirchgesner,<sup>3</sup> Vered Abitbol,<sup>4</sup> Sebastian Shaji,<sup>5</sup> Alessandro Armuzzi,<sup>6</sup> Konstantinos Karmiris,<sup>7</sup> Javier P. Gisbert,<sup>8,9</sup> Peter Bossuyt,<sup>10</sup> Ulf Helwig,<sup>11</sup> Johan Burisch,<sup>12,13</sup> Henit Yanai,<sup>14,15</sup> Glen A. Doherty,<sup>16</sup> Fernando Magro,<sup>17</sup> Tamás Molnar,<sup>18</sup> Mark Löwenberg,<sup>19</sup> Jonas Halfvarson,<sup>20</sup> Edyta Zagorowicz,<sup>21</sup> Hélène Rousseau,<sup>22</sup> Cédric Baumann,<sup>22</sup> Filip Baert,<sup>23</sup> and Laurent Beaugerie,<sup>3</sup> for the I-CARE Collaborator Group

<sup>1</sup>Department of Gastroenterology, Nancy University Hospital, University of Lorraine, Nancy, France; <sup>2</sup>Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium; <sup>3</sup>Department of Gastroenterology, Hôpital Saint-Antoine, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France; <sup>4</sup>Hopital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France; <sup>5</sup>Hull University Teaching Hospitals, Hull York Medical School, University of Hull, Hull, United Kingdom; <sup>6</sup>Department of Biomedical Sciences, Research Hospital, Humanitas University, Pieve Emanuele, Italy; <sup>7</sup>Venizeleio General Hospital, Heraklion, Greece; <sup>8</sup>Instituto de Investigación Sanitaria Princesa, Hospital Universitario de La Princesa, Madrid, Spain; <sup>9</sup>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Universidad Autónoma de Madrid, Madrid, Spain; <sup>10</sup>Imelda GI Clinical Research Center, Imelda General Hospital, Bonheiden, Belgium; <sup>11</sup>University of Kiel, Kiel, Germany; <sup>12</sup>Gastrounit, Medical Division, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark; <sup>13</sup>Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark; <sup>14</sup>IBD Center, Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, Israel; <sup>15</sup>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; <sup>16</sup>INITiative IBD Research Network, St. Vincent's University Hospital, University College Dublin, Dublin, Ireland; <sup>17</sup>Centro Hospitalar Universitário de São João, Faculdade de Medicina da Universidade do Porto, Porto, Portugal; <sup>18</sup>Department of Internal Medicine, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; <sup>19</sup>Amsterdam University Medical Center, location AMC, Amsterdam, the Netherlands; <sup>20</sup>Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; <sup>21</sup>Department of Oncological Gastroenterology, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland; <sup>22</sup>Unit of Methodology, Data Management and Statistic, Nancy University Hospital, Vandoeuvre-lès-Nancy, France; and <sup>23</sup>AZ Delta Hospital, Roeselare, Belgium

## BACKGROUND AND AIMS:

There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care. The primary objective of I-CARE (IBD Cancer and serious infections in Europe) was to assess prospectively safety concerns in IBD, with specific focus on the risk of cancer/lymphoma and serious infections in patients treated with anti-tumor necrosis factor and other biologic monotherapy as well as in combination with immunomodulators.

## METHODS:

I-CARE was designed as a European prospective longitudinal observational multicenter cohort study to include patients with a diagnosis of Crohn's disease, ulcerative colitis, or IBD unclassified established at least 3 months prior to enrollment.

## RESULTS:

A total of 10,206 patients were enrolled between March 2016 and April 2019, including 6169 (60.4%) patients with Crohn's disease, 3853 (37.8%) with ulcerative colitis, and 184 (1.8%) with a diagnosis of IBD unclassified. Thirty-two percent of patients were receiving azathioprine/thiopurines, 4.6% 6-mercaptopurine, and 3.2% methotrexate at study entry. At inclusion, 47.3% of patients were treated with an anti-tumor necrosis factor agent, 8.8% with vedolizumab, and 3.4% with ustekinumab. Roughly one-quarter of patients (26.8%) underwent prior

Abbreviations used in this paper: CD, Crohn's disease; eCRF, electronic case report form; IBD, inflammatory bowel disease; IBDu, inflammatory bowel disease unclassified; PRO, patient-reported outcome; TNF, tumor necrosis factor; UC, ulcerative colitis.

Most current article

© 2023 by the AGA Institute  
1542-3565/\$36.00

<https://doi.org/10.1016/j.cgh.2022.09.018>

**IBD-related surgery. Sixty-six percent of patients had been previously treated with systemic steroids. Three percent of patients had a medical history of cancer prior to inclusion and 1.1% had a history of colonic, esophageal, or uterine cervix high-grade dysplasia.**

**CONCLUSIONS:**

**I-CARE is an ongoing investigator-initiated observational European prospective cohort study that will provide unique information on the long-term benefits and risks of biological therapies in IBD patients. (EudraCT, Number: 2014-004728-23; ClinicalTrials.gov, Number: NCT02377258).**

*Keywords:* Inflammatory Bowel Disease; Biologics; Safety; Efficacy; I-CARE; Cancer; Lymphoma.

Inflammatory bowel diseases (IBDs), encompassing Crohn's disease (CD) and ulcerative colitis (UC), are lifelong, disabling, and incurable chronic inflammatory disorders involving the gastrointestinal tract.<sup>1,2</sup> Over the last decades, biologic therapies have revolutionized the treatment of IBD.<sup>3,4</sup> Precise and individual long-term safety profiles (malignancy, infections) of biologics as monotherapy or in combination with immunomodulators are poorly studied.

While the efficacy of immunomodulators in treating IBD was first reported in the 1960s,<sup>5</sup> the CESAME (Cancers Et Surrisque Associé aux Maladies inflammatoires intestinales en France) study evaluating the risk of lymphoproliferative disorders in patients receiving thiopurines for IBD was published 50 years later.<sup>6</sup> The CESAME study was the first nationwide prospective observational cohort which was designed to assess the possible excess risk of cancer in patients with IBD receiving thiopurines.<sup>6</sup> The CESAME cohort study demonstrated that a large cross-sectional observational cohort is able to address accurately and rapidly the long-term major safety issues associated with the prolonged use of thiopurines, with an immediate impact on guidelines.<sup>6-8</sup> Given the incidence of individual malignancies such as lymphomas or colorectal cancer in the general population with the same age distribution as seen in IBD patients (1 case for 1000 patient-years or less), a minimal number follow-up time of 30,000 patient-years is necessary to statistically demonstrate a significant excess risk of cancer associated with exposure to any drug.<sup>9-11</sup> Clinical trials, meta-analyses, and safety-dedicated registries, such as TREAT (Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry)<sup>12</sup> and ENCORE (Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy)<sup>13</sup> are underpowered to evaluate the impact of IBD therapies on the individual risk of cancer. Of note, IBD phenotype and disease activity may also impact cancer risk. This is well established for colorectal cancer<sup>9</sup> and might be similar for lymphomas. Some nationwide administrative health databases are adequately powered for demonstrating the statistical link between drug exposure and individual cancers,<sup>10</sup> but a proper adjustment for IBD phenotype and disease activity is not possible due to the lack of corresponding data in these studies. Only large statistically powered prospective observational cohort studies with a standardized

longitudinal follow-up including a robust characterization of disease phenotype and a prospective follow-up of IBD activity can evidence based assess the risk-benefit ratio of current therapeutic strategies in the biologic era.

Achieving and maintaining endoscopic remission, prevention of bowel damage, and reduction of IBD-related surgeries and hospitalizations have emerged as treatment goals in IBD patients.<sup>14,15</sup> The impact of anti-tumor necrosis factor (TNF) on the natural history of IBD (endoscopic remission, bowel damage, surgeries, and hospitalizations) beyond 1 year is unknown. The impact of anti-TNF therapy on long-term outcomes cannot be accurately studied using available clinical trial and registry databases. In order to properly assess the risk-benefit ratio of current therapeutic strategies, it was necessary to include all life-threatening events both IBD related and non-IBD related by collecting all hospitalization reports in these patients.

Real-world data coming from a very large cohort of IBD patients with a long-term follow-up are needed to address these issues.<sup>16</sup> The same duration of follow-up across included patients (as well as a low number of dropout are required to ensure the accuracy of the data). The I-CARE (IBD Cancer and serious infections in Europe) project was initiated in 2010 by capitalizing on the experience of the CESAME cohort study. Limitations of the CESAME study included the lack of information on the dose and duration of treatments exposure as well as no prospective assessment of disease activity and severity. The objective of I-CARE was to assess prospectively the presence and the extent of safety concerns anti-TNF or other biologic agents alone or in combination with thiopurines among IBD patients. In addition, I-CARE represents a unique opportunity to investigate the potential for disease modification as well as health economics assessment. These real-world data will be used to guide clinicians as well as healthcare Authorities and payers to provide the best care for IBD patients by optimizing available therapies. These findings may assist in maximizing benefits and minimizing risks among IBD patients who are candidates for biological therapy.

## Materials and Methods

### Study Design

I-CARE is a European prospective longitudinal observational multicenter cohort study. A total of 15

countries participated: Belgium, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Sweden, and the United Kingdom. All investigators are European gastroenterologists participating in the study on a voluntary basis. This project is centralized, sponsored, and coordinated by GETAID (Groupe d'Etude des Affections Inflammatoires du Tube Digestif) and supported by ECCO (European Crohn's and Colitis Organisation) and EFFCA (European Federation of Crohn's and Ulcerative Colitis Associations).

Patients  $\geq 18$  years of age with an established diagnosis of CD, UC, or IBD unclassified (UBDu) since  $\geq 3$  months were included. The diagnosis of IBD was based on internationally accepted endoscopic, radiological, or histological criteria. After obtaining an informed consent, information about personal details (mobile and home phone number, email address) was recorded and the patient informed about how to record data, using their private mobile, computer, or other electronic device during the study period. Exclusion criteria were patients unable or refusing to sign the informed consent form, or with no regular access to Internet, or receiving treatment at entry in the study with an immunomodulator other than thiopurines and methotrexate (eg, cyclosporine, tacrolimus, mycophenolate mofetil), and those currently or previously enrolled in a randomized clinical trial (if the investigational product received was blinded, and if the treatment is unknown at time of enrollment in I-CARE).

Each investigator could enroll up to 130 patients (not mandatory) who were divided into 6 predefined groups at inclusion based on ongoing IBD-related treatment at inclusion: group 1 comprised patients without IBD-related treatment or treated with any mesalamine or steroids formulations; group 2 comprised patients receiving thiopurines/methotrexate alone; group 3 comprised patients treated with anti-TNF monotherapy (without any concomitant immunosuppressant); group 4 comprised patients treated with anti-TNF therapy in combination with thiopurines or methotrexate; group 5 comprised patients treated with vedolizumab with or without any concomitant medications; and group 6 comprised patients treated with ustekinumab with or without any concomitant medications.

The primary objective of I-CARE is to assess prospectively the presence and the extent of safety concerns (cancers [especially lymphoma] and serious infections risks) for anti-TNF or other biologic alone or in combination with thiopurines among IBD patients. The safety profile of all steroid formulations is also analyzed. The 4 main secondary objectives of the I-CARE project are (1) to investigate prospectively the impact of anti-TNF or other biologic-based strategies on the natural history of IBD and their potential for disease modification by collecting validated surrogate markers such as endoscopic remission and disease complications such as bowel damage (strictures, fistulas, abscess), surgeries, and hospitalizations; (2) to assess the evolution of patient-

## What You Need to Know

### Background

There is a need to evaluate the benefit-risk ratio of current therapies in inflammatory bowel disease (IBD) patients to provide the best quality of care.

### Findings

I-CARE (IBD Cancer and serious infections in Europe) is an ongoing investigator-initiated observational European prospective cohort study that will provide unique information on the long-term benefits and risks of biological therapies in IBD patients.

### Implications for patient care

Future findings from I-CARE and substudies will likely be implemented in IBD guidelines and used to guide the decision-making process in daily practice.

reported outcomes (PROs) on a yearly basis and the impact of anti-TNF agents or other biologic on PROs in IBD; (3) to evaluate the benefit-risk ratio of strategies based on an earlier and wider use of anti-TNF or other biologic therapy for IBD; and (4) to assess the direct healthcare costs and cost efficacy of current therapeutic strategies in IBD.

### Data Collection

Each investigator selected and consented the patient and entered the baseline demographic and disease characteristic data of the patient in the electronic case report form (eCRF). The gastroenterologist who completed the e-summary form was also requested every year to validate and, if necessary, correct the information prospectively entered by the patients on a monthly basis. The gastroenterologist was also requested to evaluate yearly available endoscopic and imaging disease activity reports using a predefined and simplified scoring system.

A dedicated Web-based tool was built by SANOÏA (Marseille, France), a service provider with experience in patient e-Diary and e-PRO to capture the information coming from the patients. SANOÏA also ensured adequate reminder electronic messages to be sent to the patients for timely completion of the e-Diary and e-PRO. Patients completed the e-Diary on a monthly basis including e-PRO, hospitalizations, surgeries, and cancer diagnosis. Lifestyle factors such as smoking status and alcohol consumption were recorded at enrollment. Patients who reported hospitalization were requested to provide the related hospitalization report. Patients who reported a cancer or a high-grade dysplasia were instructed to provide the related diagnostic pathology report. An alert system was set up to inform study coordinators and project managers of incomplete data or report of hospitalization, surgery, infection, or cancer diagnostic to allow timely tracking of the pertinent documents to




Figure 1. Patient flowchart.

upload on the Web Portal. All hospitalization reports collected were coded by a dedicated expert coding group using the International Classification of Diseases–Tenth Revision classification. Details on the coding methodology will be provided in a separate article.

As the implementation of the I-CARE project across Europe at the national level was anticipated to be challenging due to differences in language, regulatory, and practical aspects; healthcare systems; and patients' journey, we gathered a core group of national coordinators (1–3 gastroenterologists per country). Their roles were to identify potential investigators, disseminate information about logistics and scientific aspects of I-CARE, translate all patients' documents and questionnaires in local language, motivate investigators, get institutional review board approval, and interact with study coordinators on a regular basis.

### Cohort Size Calculation

Calculation of cohort size was made based on the primary objective of I-CARE. We estimated, based on the CESAME study lymphoma incidence rates,<sup>6</sup> that a minimum of 47,000 patient-years was needed for the study to have a statistical power of 80% to detect a lymphoma hazard ratio of at least 3.5 in the groups of patients receiving thiopurines, either alone or in combination with anti-TNF, vedolizumab, or ustekinumab, relative to patients not receiving thiopurines (ie, receiving anti-TNF alone or no immunosuppressor).

## Results

### Patient Characteristics

From March 2016 to April 2019, 13,262 patients gave informed consent to participate in this study. Among these patients, 1 was secondarily detected as not fulfilling eligibility criteria; 2150 did not confirm their participation by not activating the e-PRO digital system; 445 activated the e-PRO digital system but did not complete any e-PRO questionnaire; 434 completed only 1-PRO questionnaire, thus generating no follow-up time;

and 26 withdrew secondarily their consent to the use of their data. Ultimately, 10,206 patients were included in the I-CARE study by 508 investigators from 15 countries (Figure 1). Clinical characteristics of the patients are summarized in Tables 1 and 2 and Supplementary Tables 1 and 2. Among the 10,206 patients, 6169 (60.4%) had CD, 3853 (37.8%) had UC, and 184 (1.8%) had IBDu. There was a female preponderance in the cohort (52.8%). The majority of patients had never smoked (54.8%). Mean body mass index at inclusion was  $24.8 \pm 4.8$  kg/m<sup>2</sup>. Approximately 75% of patients had a job, 6.8% were retired, and 9.2% were students.

A total of 1141 (11.9%) patients had a family history of IBD (11.0% for UC and IBDu patients and 12.5% for CD patients;  $P = .03$ ). Age at diagnosis of IBD was  $\leq 16$  years in 1182 (11.6%) patients, between 17 and 40 years in 7314 (71.7%) patients, and  $>40$  years in 1710 (16.8%) patients. Mean age at inclusion was  $39.8 \pm 13.1$  years. Mean disease duration at inclusion was  $10.6 \pm 8.9$  years ( $9.8 \pm 8.5$  years for UC and IBDu patients and  $11.2 \pm 9.1$  years for CD patients;  $P < .0001$ ). Location of disease at diagnosis according to Montreal classification was mainly ileocolonic in CD (42.9%) and extensive colitis in UC (45.5%). CD behavior at enrollment was inflammatory in 52% of the cases. Perianal disease was present in 27.9% of CD patients. A total of 174 (1.8%) patients had concomitant primary sclerosing cholangitis (2.3% of both the UC and IBDu patients and 1.5% of the CD patients).

At inclusion, about a quarter of patients (26.8%) underwent previous IBD-related surgery (41.7% of the CD patients, and 4.0% of the UC and IBDu patients;  $P < .0001$ ). The most frequent surgical procedures were ileocecal resection in 24.4% ( $n = 1504$  of 6169) of CD patients and perianal surgery in 13.9% ( $n = 806$  of 6169) of CD patients.

### Prior and Current Medications

IBD-related medications at study entry are summarized in Tables 3 and 4. Previous treatments before inclusion are summarized in Supplementary Tables 3, 4, and 5.

**Mesalamine.** A total of 3413 (36.4%) patients received previous treatment with oral mesalamine and



**Table 1. Baseline Characteristics**

	Total (N = 10,206)			Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])			Crohn's Disease (n = 6169 [60.4%])			P <sup>a</sup>
	n	%/Mean	SD	n	%/Mean	SD	n	%/Mean	SD	
Distribution of patients included by country										
Belgium	499	4.9		185	4.6		314	5.1		<.0001
Denmark	320	3.1		148	3.7		172	2.8		
France	2955	29.0		1007	24.9		1948	31.6		
Germany	481	4.7		208	5.2		273	4.4		
Greece	850	8.3		307	7.6		543	8.8		
Hungary	244	2.4		98	2.4		146	2.4		
Ireland	273	2.7		117	2.9		156	2.5		
Israel	298	2.9		75	1.9		223	3.6		
Italy	861	8.4		404	10.0		457	7.4		
The Netherlands	116	1.1		45	1.1		71	1.2		
Poland	80	0.8		22	0.5		58	0.9		
Portugal	267	2.6		99	2.5		168	2.7		
Spain	791	7.8		312	7.7		479	7.8		
Sweden	94	0.9		63	1.6		31	0.5		
United Kingdom	2077	20.4		947	23.5		1130	18.3		
Disease duration at inclusion, y	10206	10.6	8.9	4037	9.8	8.5	6169	11.2	9.1	<.0001
<b>Sex</b>										
Female	5385	52.8		2032	50.3		3353	54.4		<.0001
Male	4821	47.2		2005	49.7		2816	45.6		
Age at inclusion, y	10206	39.8	13.1	4037	41.5	13.7	6169	38.7	12.5	<.0001
<b>IBD subtype</b>										
Crohn's disease	6169	60.4		0	0.0		6169	100.0		<.0001
IBD unclassified	184	1.8		184	4.6		0	0.0		
Ulcerative colitis	3853	37.8		3853	95.4		0	0.0		
<b>Working status</b>										
Having a job	7644	74.9		3048	75.5		4596	74.5		<.0001
Unemployed	923	9.0		303	7.5		620	10.1		
Retired	698	6.8		337	8.3		361	5.9		
Student	941	9.2		349	8.6		592	9.6		
Body mass index, kg/m <sup>2</sup>	9384	24.8	4.8	3728	25.0	4.7	5656	24.7	4.9	.0001
<b>Smoking status</b>										
Current	1471	15.5		336	8.9		1135	19.8		<.0001
Former	2827	29.8		1199	31.8		1628	28.4		
Never	5204	54.8		2235	59.3		2969	51.8		
Missing	704			267			437			

Table 1. Continued

	Total (N = 10,206)			Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])			Crohn's Disease (n = 6169 [60.4%])			P <sup>a</sup>
	n	%/Mean	SD	n	%/Mean	SD	n	%/Mean	SD	
Alcohol consumption										
No	7715	81.0		2917	77.1		4798	83.6		<.0001
Yes	1805	19.0		864	22.9		941	16.4		
Missing	686			256			430			

IBD, inflammatory bowel disease.

<sup>a</sup>Chi-square test for qualitative variables, Wilcoxon test for quantitative variables.

2229 (23.6%) with topical mesalamine. The majority of patients who were previously treated with topical mesalamine had UC or IBDu ( $P < .0001$ ). At study entry, 3568 (35%) patients were receiving oral mesalamine and 1010 (9.9%) topical mesalamine. They were more likely to experience UC ( $P < .0001$ ).

**Corticosteroids.** A large majority of patients (65.9%) were previously treated with systemic steroids. Budesonide was previously used in 1990 (21%) patients (7.2% in UC patients and 30.1% in CD patients;  $P < .0001$ ) and budesonide MMX in 106 (1.1%) patients. At enrollment, 569 (5.6%) patients were receiving systemic corticosteroids (oral or intravenous). Budesonide was prescribed in 148 (1.5%) patients and budesonide MMX in 28 (0.3%) patients.

**Immunosuppressants/Immunomodulators.** A total of 30.7% ( $n = 3136$  of 10,206) of patients reported previous treatment with azathioprine, 6.3% ( $n = 638$  of 10,206) with methotrexate, and 4.7% ( $n = 478$  of 10,206) with 6-mercaptopurine. Among 30.7% of patients who received azathioprine prior to study entry, almost half of them (48.4%) were exposed for <1 year.

At enrollment, 3294 (32.3%) patients were receiving thiopurines, 4.6% ( $n = 468$  of 10,206) 6-mercaptopurine, and 3.2% ( $n = 325$  of 10,206) methotrexate. Patients receiving azathioprine or methotrexate were more likely to have CD compared with patients not receiving methotrexate ( $P < .0001$ ).

**Biologics.** A total of 1690 (17.8%) patients had received infliximab before entering the study. Of the enrolled patients, 1334 (14.0%) had prior use of adalimumab, 141 (1.5%) golimumab, and 60 (0.6%) certolizumab pegol. Concerning other biologics than anti-TNF, 147 (1.5%) had prior use of vedolizumab and 38 (0.4%) ustekinumab.

At study entry, 2725 (26.7%) patients were receiving infliximab, 1937 (19%) adalimumab, 149 (1.5%) golimumab, 9 (0.1%) certolizumab pegol, 894 (8.8%) vedolizumab, and 343 (3.4%) ustekinumab.

#### History of Cancer or Dysplasia

Among all included patients, 298 (2.9%) patients had a prior history of any type of cancer, including 135 UC or IBDu and 163 CD patients, (Supplementary Table 6). Moreover, 108 (1.1%) patients had a medical history of high-grade dysplasia: 20 patients had colonic high-grade dysplasia, 3 esophageal high-grade dysplasia, and 71 uterine cervix high-grade dysplasia. There was no difference between UC and CD patients. A total of 1085 (11.3%) patients had a family history (first-degree relative) of any of the following cancer: lymphoma, colorectal cancer, melanoma, or breast cancer (Supplementary Table 1).

#### History of Vaccination and Infection

Vaccination rate was 6.2% for human papillomavirus vaccine, 56.5% for hepatitis B vaccine, 35.1% for

Table 2. Disease Characteristics

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
Age at diagnosis							<.0001
(A1) 16 y and below	1182	11.6	325	8.1	857	13.9	
(A2) between 17 and 40 y included	7314	71.7	2848	70.5	4466	72.4	
(A3) 41 y and above	1710	16.8	864	21.4	846	13.7	
CD location (L1, L2, L3)							
(L1) ileal, including caecum	2172	37.9			2172	37.9	
(L2) colonic	1100	19.2			1100	19.2	
(L3) ileocolonic	2463	42.9			2463	42.9	
Missing	434				434		
CD behavior (B1, B2, B3)							
(B1) nonstricturing, nonpenetrating	2976	52.0			2976	52.0	
(B2) stricturing	1613	28.2			1613	28.2	
(B3) penetrating	1134	19.8			1134	19.8	
Missing	446				446		
Any perianal disease							
No	4145	72.1			4145	72.1	
Yes	1606	27.9			1606	27.9	
Missing	418				418		
UC involvement (E1, E2, E3)							
(E1) Proctitis	551	14.6	551	14.6			
(E2) Left sided colitis	1501	39.9	1501	39.8			
(E3) Extensive UC	1714	45.5	1715	45.5			
Missing	271		271				
Cumulative estimated microscopic and/or macroscopic extend of the surface of colonic mucosa							<.0001
0%	2321	27.3	436	13.0	1885	36.8	
0%–50%	3210	37.8	1396	41.5	1814	35.4	
50%–100%	2961	34.9	1533	45.6	1428	27.9	
Missing	1714		672		1042		
Associate confirmed primary sclerosing cholangitis							.0031
No	9262	98.2	3657	97.7	5605	98.5	
Yes	174	1.8	88	2.3	86	1.5	
Missing	770		292		478		

CD, Crohn's disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.  
<sup>a</sup>Chi-square test.

pneumococcus vaccine, and 53.9% for Bacille Calmette-Guerin vaccine (Supplementary Table 7). A confirmed history of symptomatic mononucleosis infection was reported in 376 (5%) patients, including 140 UC or IBDu and 236 CD patients before inclusion.

## Discussion

I-CARE is the first prospective cohort study that is specifically designed to assess the risk-benefit ratio of current therapeutic strategies in the biologic era in patients with IBD. I-CARE is a European collaborative effort involving 15 countries. A total of 10,206 IBD patients were enrolled between March 2016 and April 2019.

To reach the I-CARE objectives, we developed innovative tools like a dedicated Web-based tool to capture the information (e-Diary and e-PRO) coming from the patients, and a second platform to house the investigators database and eCRF completed by the investigators (Supplementary Figure 1). An interface was built between these 2 systems to allow enrollment of patients after the investigators completed their contact information on the eCRF and investigators to have a summary of data entered by their patients for validation.

One of the strengths of the I-CARE project was the quality of data collection (Table 5). The patient had a central role in the investigation. However, patient data were annually reviewed and validated by their gastroenterologist. For cancer, dysplasia, any IBD-related and

**Table 3.** Ongoing Immunomodulator, Corticosteroid, and Mesalamine Treatments at Entry

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
Any oral form of mesalamine (oral)							<.0001
No	6638	65.0	1473	36.5	5165	83.7	
Yes	<b>3568</b>	<b>35.0</b>	<b>2564</b>	<b>63.5</b>	<b>1004</b>	<b>16.3</b>	
Any topical forms of mesalamine (suppository, foam, enema)							<.0001
No	9196	90.1	3103	76.9	6093	98.8	
Yes	1010	9.9	934	23.1	76	1.2	
Any form of systemic corticosteroids							<.0001
No	9637	94.4	3721	92.2	5916	95.9	
Yes	569	5.6	316	7.8	253	4.1	
Corticosteroids: administration of treatment							.1963
Intravenous	11	1.9	4	1.3	7	2.8	
Oral	558	98.1	312	98.7	246	97.2	
Budesonide (oral)							<.0001
No	10,058	98.5	4018	99.5	6040	97.9	
Yes	148	1.5	19	0.5	129	2.1	
Budesonide MMX (oral)							<.0001
No	10,178	99.7	4015	99.5	6163	99.9	
Yes	28	0.3	22	0.5	6	0.1	
Beclometasone (oral)							<.0001
No	10,186	99.8	4019	99.6	6167	100.0	
Yes	20	0.2	18	0.4	1	0.0	
Azathioprine							<.0001
No	6912	67.7	2890	71.6	4022	65.2	
Yes	3294	32.3	1147	28.4	2147	34.8	
6-Mercaptopurine							.2819
No	9738	95.4	3863	95.7	5875	95.2	
Yes	468	4.6	174	4.3	294	4.8	
Methotrexate							<.0001
No	9881	96.8	3969	98.3	5912	95.8	
Yes	325	3.2	68	1.7	257	4.2	

IBD = inflammatory bowel disease.

non-IBD-related hospitalizations, and surgeries, the corresponding hospitalization and histological reports were collected. Collected comorbidities are alcohol, smoking, and body mass index. From the hospitalization reports, we will be able to collect other comorbidities and perform a nested case-control study.

The majority of patients had a CD diagnosis in I-CARE (60.4%), this rate was similar to the CESAME study (60.3%).<sup>7</sup> Age at diagnosis of IBD was similar to the previous study, with a large majority of patients diagnosed between 17 and 40 years of age.<sup>17</sup> Concerning the Montreal classification and the presence of perianal lesions, our data were consistent with the literature.<sup>18</sup> As expected, in I-CARE, patients were more likely to be

treated with biologics than in other databases.<sup>19,20</sup> Even though I-CARE is not a population-based study because of a large sample size, baseline characteristics are those commonly observed in European studies underscoring its validity and representativeness.<sup>19,20</sup>

The primary focus of I-CARE was to address the lymphoma risk, including other malignancies, as well as serious infections in IBD patients exposed to biologics. Based on the CESAME study experience, to minimize potential bias and confounding effects for evaluation of the effect of each treatment exposure on the occurrence of severe infection, cancer, and hospitalization, the propensity score (using all details of IBD phenotype and history) for each treatment will be or was calculated



March 2023

Safety and Effectiveness of Biologics in IBD 779

Table 4. Ongoing Biological Treatments at Entry

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
<b>Biological treatments</b>							<.0001
Adalimumab	1937	19.0	262	6.5	1675	27.2	
Certolizumab Pegol	9	0.1	1	0.0	8	0.1	
Golimumab	149	1.5	137	3.4	12	0.2	
Infliximab	2725	26.7	853	21.1	1872	30.3	
None	4149	40.6	2280	56.5	1869	30.3	
Ustekinumab	343	3.4	12	0.3	331	5.4	
Vedolizumab	894	8.8	492	12.2	402	6.5	
<b>Infliximab: estimated duration of treatment before entry in I-CARE</b>							<.0001
<1 y	780	28.6	303	35.5	477	25.5	
1 y	363	13.3	129	15.1	234	12.5	
2 y	353	13.0	117	13.7	236	12.6	
3 y	260	9.5	72	8.4	188	10.0	
4 y	217	8.0	66	7.7	151	8.1	
5 y	162	5.9	43	5.0	119	6.4	
6 y	143	5.2	36	4.2	107	5.7	
7 y	113	4.1	25	2.9	88	4.7	
8 y	80	2.9	22	2.6	58	3.1	
9 y	70	2.6	16	1.9	54	2.9	
10 y and more	182	6.7	24	2.8	158	8.4	
Missing	2		0		2		
<b>Adalimumab: estimated duration of treatment before entry in I-CARE</b>							<.0001
<1 y	564	29.1	109	41.6	455	27.2	
1 y	297	15.3	47	17.9	250	14.9	
2 y	319	16.5	40	15.3	279	16.7	
3 y	211	10.9	19	7.3	192	11.5	
4 y	183	9.4	21	8.0	162	9.7	
5 y	97	5.0	9	3.4	88	5.3	
6 y	81	4.2	6	2.3	75	4.5	
7 y	75	3.9	3	1.1	72	4.3	
8 y	41	2.1	4	1.5	37	2.2	
9 y	28	1.4	1	0.4	27	1.6	
10 y and more	37	1.9	3	1.1	34	2.0	
Missing	4		0		4		
<b>Certolizumab pegol: estimated duration of treatment before entry in I-CARE</b>							.6667
<1 y	2	22.2	1	100.0	1	12.5	
1 y	3	33.3	0	0.0	3	37.5	
2 y	1	11.1	0	0.0	1	12.5	
3 y	1	11.1	0	0.0	1	12.5	
4 y	1	11.1	0	0.0	1	12.5	
7 y	1	11.1	0	0.0	1	12.5	
<b>Golimumab: estimated duration of treatment before entry in I-CARE</b>							.1842
<1 y	76	51.0	71	51.8	5	41.7	
1 y	36	24.2	34	24.8	2	16.7	
2 y	25	16.8	23	16.8	2	16.7	
3 y	10	6.7	7	5.1	3	25.0	
4 y	2	1.3	2	1.5	0	0.0	
<b>Vedolizumab: estimated duration of treatment before entry in I-CARE</b>							.3220
<1 y	576	64.5	325	66.1	251	62.6	
1 y	187	20.9	93	18.9	94	23.4	
2 y	97	10.9	57	11.6	40	10.0	
3 y	24	2.7	11	2.2	13	3.2	
4 y	7	0.8	5	1.0	2	0.5	

Table 4. Continued

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
5 y	1	0.1	1	0.2	0	0.0	
8 y	1	0.1	0	0.0	1	0.2	
Missing	1		0		1		
Ustekinumab: estimated duration of treatment before entry in I-CARE							.0950
<1 y	237	69.1	10	83.3	227	68.6	
1 y	55	16.0	0	0.0	55	16.6	
2 y	36	10.5	0	0.0	36	10.9	
3 y	8	2.3	2	16.7	6	1.8	
4 y	2	0.6	0	0.0	2	0.6	
5 y	2	0.6	0	0.0	2	0.6	
6 y	1	0.3	0	0.0	1	0.3	
7 y	1	0.3	0	0.0	1	0.3	
8 y	1	0.3	0	0.0	1	0.3	

I-CARE, IBD Cancer and serious infections in Europe; IBD, inflammatory bowel disease.

<sup>a</sup>Chi-square test or Fisher's exact test.

using logistic regression models. To overcome the main limitations of the CESAME project, we prospectively assessed clinical disease activity in IBD patients through prospective monthly assessments (Harvey-Bradshaw index for CD and Simple Clinical Colitis Activity Index for UC), and disease activity and severity through a scoring system of imaging and endoscopic reports. To this end, we were able to adjust for IBD activity the relationship between drug exposures and outcomes. We also recorded and quantified the exposure to IBD drugs of interest from IBD diagnosis, prior to the enrollment into the cohort, in order to be able to address the potential link between the cumulative dose of drug exposure and the late occurrence of malignancies. For the first time, we have collected all IBD treatments received since IBD

diagnosis (every course, every drug class, every date of start and duration of treatment). Only the precise dose was not collected before I-CARE entry. Finally, we recorded family histories of lymphoma, colorectal cancer, melanoma, and breast cancer that have been shown to have a key role in the individual cancer risks. The statistical power and granularity of I-CARE will provide unique information on the relationships between IBD drugs and efficacy and safety outcomes in the biologics era.

Regarding the obstacles encountered during the I-CARE project, it was necessary to convince countries with existing national cohort to participate in the I-CARE project, obtain regulatory approval across countries, develop authorship rules, organize regular meetings at international conferences to inform and motivate

Table 5. Strengths of I-CARE

1. Large statistically powered prospective observational cohort study
2. Real-world data
3. Standardized longitudinal follow-up
4. Long-term follow-up
5. Quality of data collection
6. Primary objective: to assess prospectively the presence and the extent of safety concerns (cancers (especially lymphoma) and serious infections risks) for anti-TNF or other biologic alone or in combination with thiopurines
7. Secondary objectives:
- To investigate prospectively the impact of anti-TNF or other biologic based strategies on the natural history of IBD and their potential for disease modification
- To assess the evolution of PROs on a yearly basis and the impact of anti-TNF agents or other biologic on PROs in IBD
- To evaluate the benefit-risk ratio of strategies based on an earlier and wider use of anti-TNF or other biologic therapy for IBD
- To assess the direct healthcare costs and cost efficacy of current therapeutic strategies in IBD

I-CARE, IBD Cancer and serious infections in Europe; IBD, inflammatory bowel disease; PRO, patient-reported outcome; TNF, tumor necrosis factor.

collaborators, and define a precise task distribution given the number of people involved in this project.

Future findings from I-CARE and substudies will likely be implemented in IBD guidelines and used to guide the decision-making process in daily practice.

## Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Clinical Gastroenterology and Hepatology* at [www.cghjournal.org](http://www.cghjournal.org), and at <http://doi.org/10.1016/j.cgh.2022.09.018>.

## References

- Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. *Lancet* 2017;389:1741–1755.
- Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. *Lancet* 2012;380:1606–1619.
- De Felice KM. Patients perception of risks and benefits of biologic therapy. *Inflamm Bowel Dis* 2020;26:147–149.
- D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. *Lancet* 2008;371:660–667.
- Brooke BN, Hoffmann DC, Swarbrick ET. Azathioprine for Crohn's disease. *Lancet* 1969;2:612–614.
- Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet* 2009;374:1617–1625.
- Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. *Gastroenterology* 2011;141:1621–1628.e1–5.
- Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. *J Crohns Colitis* 2015;9:945–965.
- Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. *N Engl J Med* 2015;372:1441–1452.
- Lemaitre M, Kirchgessner J, Rudnicki A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. *JAMA* 2017;318:1679–1686.
- Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor- $\alpha$  antagonists and risk of cancer in patients with inflammatory bowel disease. *JAMA* 2014;311:2406–2413.
- Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn's disease: more than 13 years of real-world experience. *Inflamm Bowel Dis* 2018;24:490–501.
- D'Haens G, Reinisch W, Colombel JF, et al. Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn's disease treated with infliximab [Remicade®] or conventional therapy. *J Crohns Colitis* 2017;11:680–689.
- Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. *Curr Opin Gastroenterol* 2013;29:397–404.
- Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study

of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. *Gastroenterology* 2021;160:1570–1583.

- Le Berre C, Peyrin-Biroulet L, SPIRIT-IOIBD study group. Selecting end points for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD. *Gastroenterology* 2021;160:1452–1460.e21.
- Duricova D, Burisch J, Jess T, et al. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. *J Crohns Colitis* 2014;8:1351–1361.
- Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology* 2011;140:1785–1794.
- Burisch J, Katsanos KH, Christodoulou DK, et al. Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort—An Epi-IBD study. *J Crohns Colitis* 2019;13:198–208.
- Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. *Gut* 2019;68:423–433.

## Correspondence

Address correspondence to: Laurent Peyrin-Biroulet, MD, PhD, Inserm NGERE U1256 and Department of Gastroenterology, Nancy University Hospital, University of Lorraine, 1 Allée du Morvan, 54511 Vandœuvre-lès-Nancy, France. e-mail: [peyrinbiroulet@gmail.com](mailto:peyrinbiroulet@gmail.com); fax: (+33) 383153633.

## Acknowledgments

The authors thank all the patients for their active participation in the project. The authors thank their partners: AbbVie, Amgen, Ferring, Pfizer, Janssen, MSD, and Takeda. The Master ICARE Protocol received an approval from Saint Louis Ethic Committee on 15/05/2015 and CNIL approval on 27/10/2015. Each country participating in I-CARE had the responsibility to submit the protocol and the amendments in agreement with their own local regulation. N° INDS: TP305083; CERES approval on February 20, 2019.

**I-CARE Collaborator Group:** Jean-Marc GORNET, Hôpital Saint-Louis, Université Paris Nord, Paris, France; Laurent BEAUGERIE, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; Sebastian SHAJI, Hull University Teaching Hospitals, Hull York Medical School – University of Hull, Hull, United Kingdom; Laurent PEYRIN-BIROULET, CHRU Nancy, Nancy University, Nancy, France; Jean-Marie REIMUND, Hôpital universitaire de Strasbourg, Université de Strasbourg, Strasbourg, France; Xavier HEBUTERNE, Hôpital L'archet, Nice, France; Aurélien AMIOT, Hôpital Henri Mondor Université Paris Est, Créteil, France; Franco ARMELAO, Ospedale Santa Chiara, Azienda Provinciale per i Servizi Sanitari, Trento, Italy; Pierre BLANC, CHU Montpellier, Université de Montpellier, Montpellier, France; Claudio PAPI, Ospedale San Filippo Neri, Roma, Italy; Guillaume PINETON DE CHAMBRUN, Hôpital Saint-Eloi, Université de Montpellier, Montpellier, France; Xavier ROBILIN, CHU Saint-Etienne, Saint-Etienne Université, Saint-Etienne, France; Konstantinos KARMIRIS, Venizeleio General Hospital, Heraklion, Greece; Sohail SHARIC, Ealing Hospital, Imperial College London, London, United Kingdom; Nikolaos VIAZIS, Evangelismos General Hospital, Athens, Greece; Jimmy LIMDI, Northern Care Alliance NHS Foundation Trust, University of Manchester, Manchester, United Kingdom; Piotr EDER, H. Świecicki University Hospital, Poznan University of Medical Sciences, Poznan, Poland; Georgios MICHALOPOULOS, Tzaneion General Hospital, Piraeus, Greece; Andrew BELL, Weston General Hospital, Weston-Super-Mare, United Kingdom; Livia BIANCONE, Policlinico Tor Vergata, Università di Roma Tor Vergata, Roma, Italy; Marie DEWITTE, CHU Rennes – Hôpital Pontchaillou, Université Rennes 1, Rennes, France; Zia MAZHAR, Basildon and Thurrock University Hospitals NHS Trust, Basildon, United Kingdom; Denis FRANCHIMONT, Erasmus Hospital, VUB-ULB, Brussels, Belgium; Stephane NANCEY, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; Gilles MACAIGNE, CH Marne la vallée, Jossigny, France; Maria Beatrice PRINCIPI, Policlinico di Bari, Università di Bari, Bari, Italy; Mathurin FUMERY, CHU Amiens, Université de Picardie Jules Verne, Amiens, France; Gareth PARKES, St Bartholomew's Hospital, Queen Mary University of London, London, United Kingdom; Jean-Christophe VALATS, CHU Montpellier, Université de Montpellier, Montpellier, France; Glen DOHERTY, St Vincent University Hospital & University College Dublin, Dublin, Ireland; Guillaume BOUGUEN, CHU Rennes – Hôpital Pontchaillou, Université Rennes 1, Rennes, France; Tamás MOLNAR, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; Hersin TSAI, Hull University Teaching Hospitals, Hull York Medical School – University of Hull, Hull, United Kingdom; Mohsin GANGI, Stepping Hill Hospital, Stockport, United Kingdom; Natalia PEDERSEN,

Slagelse Hospital, University of Copenhagen, Slagelse, Denmark; **Frédéric HELUWAERT**, CH Ancey Genevois, Ancey, France; **Richard SHENDEREY**, Airedale General Hospital, Leeds University School of Medicine, Airedale, United Kingdom; **Sebastian ZEISSIG**, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; **Jeffrey BUTTERWORTH**, Royal Shrewsbury Hospital, Keele University School of Medicine, Staffordshire University, Shrewsbury, United Kingdom; **Fabiana CASTIGLIONE**, Policlinico Federico II, Università Federico II, Napoli, Italy; **Lynsey CORLESS**, Hull University Teaching Hospitals, Hull York Medical School – University of Hull, Hull, United Kingdom; **Camille ZALLOT**, CHRU Nancy, Université de Nancy, Nancy, France; **Filip BAERT**, AZ Delta, campus Rumbek, Roesselare, Belgium; **Salil SINGH**, Royal Bolton Hospital, Bolton, United Kingdom; **Sunil SONWALKAR**, Calderdale Royal Hospital, Halifax, United Kingdom; **Julie BURTON**, Pinderfields Hospital, Wakefield, United Kingdom; **Elizabeth CLAYTON**, Pinderfields Hospital, Wakefield, United Kingdom; **Jean-François RAHIER**, CHU Namur, site Godinnee, University of Namur, Namur, Belgium; **Deven VANI**, Pinderfields Hospital, Wakefield, United Kingdom; **Renata D'INCA**, Ospedale di Padova, Università di Padova, Padova, Italy; **Guy BELLAICHE**, Hôpital Robert Ballanger, Université de Bobigny, Aulnay-sous-bois, France; **Martine DE VOS**, UZ Ghent, Ghent University, Ghent, Belgium; **Julien KIRCHGESNER**, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; **Uri KOPYLOV**, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Triana LOBATON**, UZ Ghent, Ghent University, Ghent, Belgium; **Christophe LOCHER**, Hôpital de Meaux, Meaux, France; **Gerassimos MANTZARIS**, Evangelismos General Hospital, Athens, Greece; **George ABOUDA**, Hull University Teaching Hospitals, Hull York Medical School – University of Hull, Hull, United Kingdom; **Katie SMITH**, Michael SPRAKES, Pinderfields Hospital, Wakefield, United Kingdom; **Yeovil District Hospital**, Yeovil, United Kingdom; **Angeliki THEODOROPOULOU**, Venizeleio General Hospital, Heraklion, Greece; **Emma WESLEY**, Musgrove Park Hospital, Taunton, United Kingdom; **Joëlle BONNET**, Hôpital Saint-Louis, Université Paris Nord, Paris, France; **David ELPHICK**, Chesterfield Royal Hospital, Chesterfield, United Kingdom; **Cyrielle GILLET**, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; **John GORDON**, Hampshire Hospitals, University of Southampton, Basingstoke, United Kingdom; **David LAHARIE**, CHU Bordeaux, Université de Bordeaux, Pessac, France; **Antoine NAKAD**, Chwapi Hospital, Tournai, Belgium; **Ambrogio ORLANDO**, Ospedale V. Cervello, Università di Palermo, Palermo, Italy; **Patrick DUBOIS**, Kings College Hospital, King's College London, London, United Kingdom; **Peter HASSELBLATT**, Universitätsklinikum Freiburg, Universitätsklinikum Freiburg, Freiburg, Germany; **Christophe MICHIELS**, CHU Dijon, Dijon, France; **Cathryn PRESTON**, Bradford Teaching Hospitals, Leeds School of Medicine, Bradford, United Kingdom; **Anca STAIU**, Hull University Teaching Hospitals, Hull York Medical School/University of Hull, Hull, United Kingdom; **Lucine VUITTON**, CHU de Besançon – UMR, Université de Besançon, Franche-comté, France; **Mehdi KAASSIS**, Centre Hospitalier de Cholet, Cholet, France; **Aly SPEIGHT**, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, United Kingdom; **Deb GHOSH**, Princess Alexandra Hospital, Harlow, United Kingdom; **Mark LÖWENBERG**, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands; **Nicolas MATHIEU**, CHU Grenoble, Université Grenoble Alpes, Grenoble, France; **Anne-Laure PELLETIER**, Groupe Hospitalier Bichat-Claude Bernard, Paris, France; **Anne PHILLIPS**, York Hospital, Hull York Medical School, York, United Kingdom; **Fernando MAGRO**, Centro Hospitalar Universitário de São João, Faculty of Medicine of the University of Porto, Porto, Portugal; **Romain ALTWEGG**, Hôpital Saint-Eloi, Montpellier, France; **Irit AVNI BIRON**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Jonathon LANDY**, Watford General Hospital, Watford, United Kingdom; **Maria NACHURY**, CHU Lille, Université Lille, Lille, France; **Achuth SHENOY**, Colchester General Hospital, Barts and The London School of Medicine and Dentistry, Norwich Medical School, Anglia Ruskin University, Colchester, United Kingdom; **Caroline TRANG**, CHU Nantes, Université Nantes, Nantes, France; **Vered ABITBOL**, Hôpital Cochin AP-HP, Université Paris Cité, Paris, France; **Georgios BAMIAS**, Sotiria General Hospital, National and Kapodistrian University, Athens, Greece; **Klaudia FARKAS**, Albert Szent-Györgyi Health center, University of Szeged, Szeged, Hungary; **Christian MAASER**, Klinikum Lüneburg, Klinikum Lüneburg, Lüneburg, Germany; **Ariella SHITRIT**, Shaare Tzedek Medical Center, Hebrew University, Jerusalem, Israel; **Britta SIEGMUND**, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; **Jérôme FILIPPI**, Hôpital L'archet, Nice, France; **Colm O'MORAIN**, Beacon Hospital, UCD, Dublin, Ireland; **Henit YANAI**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Laurent COSTES**, Centre hospitalier intercommunal de Créteil, Créteil, France; **David HOBDAI**, Sunderland Royal Hospital, Sunderland, United Kingdom; **Zoltán SZEPES**, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; **Emma CALABRESE**, Policlinico Tor Vergata, Università di Roma Tor Vergata, Roma, Italy; **Helen DALLAL**, James Cook University Hospital, Durham University, Newcastle University, Middlesbrough, United Kingdom; **Michael FUNG**, NHS Plymouth, Plymouth, United Kingdom; **Arvind RAMADAS**, James Cook University Hospital, Durham University, Newcastle University, Middlesbrough, United Kingdom; **Bijay BABURAJAN**, Maidstone Hospital, Maidstone, United Kingdom; **Konrad KOSS**, Macclesfield District General Hospital, Macclesfield, United Kingdom; **Christophe BARBERIS**, Hôpital Bagatelle, Talence, France; **Anthony BUISSON**, CHU Clermont-Ferrand, Inserm U1071, M2ISH, Université Clermont Auvergne, Clermont-Ferrand, France; **Morgane AMIL**, CHD Vendée, La Roche-sur-Yon, France; **Paola BALESTRERI**, Campus Biomedico, Università Campus Biomedico, Roma, Italy; **Matthew JOHNSON**, Luton and Dunstable University Hospital, University College London, Luton, United Kingdom; **Maria TZOUVALA**, Agios Panteleimon General Hospital,

Nikaia-Piraeus, Greece; **Stéphanie VIENNOT**, CHU Caen, Université de Caen, Caen, France; **Andy LI**, Worthing Hospital, Worthing, United Kingdom; **Ferenc NAGY**, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; **Nick THOMPSON**, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, United Kingdom; **Laurent ALRIC**, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; **Sunil SAMUEL**, Nottingham University Hospitals NHS Trust Queen's Medical Centre, Nottingham, United Kingdom; **Anne BOURRIER**, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; **Elise CHANTELOUP**, Hôpital Paris Saint-Joseph, Paris, France; **Emilie DEL TEDESCO**, CHU Saint-Etienne, Université Saint-Etienne, Saint-Etienne, France; **Marcus HARBORD**, Chelsea and Westminster Hospital, Imperial College London, London, United Kingdom; **Alan LOBO**, Royal Hallamshire Hospital, University of Sheffield, Sheffield, United Kingdom; **Sally MYERS**, Hull University Teaching Hospitals, Hull York Medical School – University of Hull, Hull, United Kingdom; **Richard POLLOK**, St George's Hospital, University of London, London, United Kingdom; **Tariq AHMAD**, Royal Devon and Exeter Hospital, University of Exeter Medical School, Exeter, United Kingdom; **Rakesh CHAUDHARY**, Watford General Hospital, Watford, United Kingdom; **Kristos KARAKOUIDAS**, Naval Hospital, Athens, Greece; **Edouard LOUIS**, CHU de Liège, Liège, Belgium; **Ashraf SOLIMAN**, Barnsley General Hospital, University of Sheffield, Barnsley, United Kingdom; **Carmen STEFANESCU**, Hôpital Beaujon, Université Paris, Clichy, France; **Georgios THEOPHARIS**, University Hospital of Patra, Patra, Greece; **Stijn VANDEN BRANDEN**, OLV-Aalst, Aalst, Belgium; **Belén BELTRAN**, Hospital Universitari La Fe – Instituto de Investigación Sanitaria La Fe (IISLaFe), Polytechnic University of Valencia, Valencia, Spain; **Yoram BOUHNIC**, Hôpital Beaujon, Université de Paris, Clichy, France; **Arnaud BOURREILLE**, CHU Nantes, Université de Nantes, Nantes, France; **Joana BRANCO**, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal; **Ben COLLEYPRIEST**, Royal United Hospitals Bath, Bath, United Kingdom; **Rami ELIAKIM**, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Paul KNIGHT**, Wythenshawe Hospital, University of Manchester, Manchester, United Kingdom; **Aoihlinn O'TOOLE**, Beaumont Hospital, RCSI, Dublin, Ireland; **Virginia ROBLES**, Hospital Vall d'Hebron, Universidad autonoma de Barcelona, universitat oberta de catalunya, Barcelona, Spain; **Konstantinos TRIANTAFYLLOU**, Attikon University Hospital, National and Kapodistrian University, Athens, Greece; **Marta Maia BOSCA**, Hospital Clínico Universitario de Valencia, University of Valencia, Valencia, Spain; **Quy LAM-BRECHT**, AZ Damaïan, Ostend, Belgium; **Lucia MARQUEZ MOSQUERA**, Hospital del Mar, Barcelona, Pompeu Fabra University, Barcelona, Spain; **Simon PANTER**, South Tyneside District Hospital, South Shields, United Kingdom; **Aikaterini PAPPA**, University Hospital of Larissa, Larissa, Greece; **Marion SIMON**, Institut Mutualiste Montsouris, Paris, France; **Ganesh SNAJI**, Harrogate District Hospital, Harrogate, United Kingdom; **Christophe BELLANGER**, Kremlin Bicêtre, Université Paris Saclay, Le Kremlin Bicêtre, France; **Arthur BELLE**, CHRU Nancy, Université de Nancy, Nancy, France; **Natalia BORRUEL**, Hospital Vall d'Hebron and Centro de Investigación Biomédica en Red de enfermedades Hepáticas y Digestivas (CIBEREHD), Autonomous University of Barcelona, Barcelona, Spain; **Laurence EGAN**, UCHG, NUIG, Galway, Ireland; **Harald PEETERS**, AZ St-Lucas, Ghent, Ghent, Belgium; **Daniel SHARPSTONE**, West Suffolk Hospital, University of Suffolk, Suffolk, United Kingdom; **Ramesh ARASARADNAM**, University Hospital Coventry, University of Warwick, Coventry, United Kingdom; **José Manuel BENITEZ**, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), University of Córdoba, Córdoba, Spain; **Jens Frederik DAHLERUP**, Aarhus University Hospital, University of Aarhus, Aarhus, Denmark; **Olga GIOULEME**, Hippokraton General Hospital, Aristotle University, Thessaloniki, Greece; **Javier P. GISBERT**, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Autonomous University of Madrid (UAM), Madrid, Spain; **Ulf HELWIG**, Internistische Praxengemeinschaft Oldenburg, University of Kiel, Germany; **Miguel MINGUEZ**, Hospital Clínico Universitario de Valencia, University of Valencia, Valencia, Spain; **Eftychia TSIRONI**, Metaxa Memorial General Hospital, Piraeus, Greece; **Angela VARIOLA**, Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Italy; **Patrick ALLEN**, Ulster Hospital, Belfast, United Kingdom; **Lucille BOIVINEAU**, Hôpital Saint-Eloi, Montpellier, France; **Andy COLE**, Royal Derby Hospitals, Derby, United Kingdom; **Nina DIB**, CHU Angers, Université Angers, Angers, France; **Fernando GOMOLLON**, Hospital Clínico Universitario "Lozano Blesa", Instituto de Investigación Sanitaria de Aragón (IIS-Aragón), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Zaragoza, Zaragoza, Spain; **Richard JOHNSTON**, Torbay Hospital, Torquay, United Kingdom; **Konstantinos KATSANOS**, University Hospital of Ioannina, University of Ioannina, Ioannina, Greece; **Nick KENNEDY**, Royal Devon and Exeter Hospital, University of Exeter Medical School, Exeter, United Kingdom; **Marianne KISZKANOWITZ**, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark; **Ignacio MARIN-JIMENEZ**, Hospital Universitario Gregorio Marañón, IISGM, Complutense University of Madrid, Madrid, Spain; **Pál MIHELLER**, 1st Department of Surgery and Interventional Gastroenterology, Semmelweis University, Budapest, Hungary; **Pilar NOS**, Hospital Universitario La Fe, Instituto de Investigación Sanitaria La Fe (IISLaFe), Universidad Politécnica de Valencia, Valencia, Spain; **Othman SARAJ**, Scarborough Hospital, Hull York Medical School, Scarborough, United Kingdom; **Lars VINTER-JENSEN**, Aalborg University Hospital, University of Aalborg, Aalborg, Denmark; **Eran ZITAN**, Haemeq Medical Center, Faculty of Medicine Technion, Afula, Israel; **Cloilde BAUDRY**, Hôpital Saint-Louis, Université Paris Nord, Paris, France; **Xavier CALVET**, Hospital Universitari Parc Taulí, Autonomous University of Barcelona, Sabadell,



Spain; **Marie-Christine CAZELLES-BOUDIER**, Centre Hospitalier de la Côte Basque, Bayonne, France; **Jean-Louis COENEGRACHTS**, Jessa Ziekenhuis Hospital, Hasselt, Belgium; **Garret CULLEN**, St Vincent University Hospital & University College Dublin, Dublin, Ireland; **Marco DAPERNO**, Ospedale Ordine Mauriziano Umberto I, Università di Torino, Torino, Italy; **Anjan DHAR**, Darlington Memorial Hospital, Durham, United Kingdom; **Romain GERARD**, CHU Lille, Université de Lille, Lille, France; **Christian Lodberg HVAS**, Aarhus University Hospital, University of Aarhus, Aarhus, Denmark; **Nanna JENSEN**, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark; **Nitsan MAHARSHAK**, Sourasky Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Mark MCALINDON**, Royal Hallamshire Hospital, University of Sheffield, Sheffield, United Kingdom; **Simon MCLOUGHLIN**, Christchurch Hospital, Christchurch, United Kingdom; **Miles PARKES**, Addenbrookes's Hospital, University of Cambridge, Cambridge, United Kingdom; **Kamal PATEL**, St George's Hospital, University of London, London, United Kingdom; **Armando PEIXOTO**, Centro Hospitalar Universitário de São João, Faculty of Medicine of the University of Porto, Porto, Portugal; **Dimitrios POLYMEROS**, Attikon University Hospital, Athens, Greece; **Francisco PORTELA**, Centro Hospitalar Universitario de Coimbra, Coimbra, Portugal; **Rodolfo ROCCA**, Ospedale Ordine Mauriziano Umberto I, Università di Torino, Torino, Italy; **Philippe SEKSIK**, Hôpital Saint Antoine, Sorbonne Université, Paris, France; **Sreedhar SUBRAMANIAN**, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; **Ruth TENNENBAUM**, Centre Hospitalier Poissy St Germain-en-Laye, St Germain-en-Laye, France; **Raja ATREYA**, Universitätsklinikum Erlangen, Universitätsklinikum Erlangen, Erlangen, Germany; **Oliver BACHMANN**, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; **Arthur BERGER**, CHU Angers, Université Angers, Angers, France; **Renata BOR**, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; **Maire BUCKLEY**, St Vincent University Hospital & University College Dublin, Dublin, Ireland; **Daniel CARPIO**, Complejo Hospitalario Universitario de Pontevedra, University of Alcalá de Henares and the University of Granada, Pontevedra, Spain; **Maria CHAPARRO**, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Autonomous University of Madrid (UAM), Madrid, Spain; **Francesco COSTA**, Azienda ospedaliero-universitaria pisana, Università di Pisa, Pisa, Italy; **Eugeni DOMENECH**, Hospital Universitari Germans Trias i Pujol Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat Autònoma Barcelona, Badalona, Spain; **Maria ESTEVE**, Hospital Universitari Mutua Terrassa, Centro Investigación biomédica en red de enfermedades hepáticas y digestivas, University of Barcelona, Barcelona, Spain; **Stephen FOLEY**, King's Mill Hospital, University of Nottingham, Sutton-in-Ashfield, United Kingdom; **Jordi GUARDIOLA**, Hospital Universitario de Bellvitge, IDIBELL, Universidad de Barcelona, Hospitalet del Llobregat, Spain; **Ioannis KOUTROUBAKIS**, University Hospital of Heraklion, University of Crete, Heraklion, Greece; **Tanja KUEHBACHER**, Medius Kliniken Nürtingen, Medius Kliniken Nürtingen, Nürtingen, Germany; **Cécilia LANDMAN**, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; **Alessandro LAVAGNA**, Ospedale Ordine Mauriziano Umberto I, Università di Torino, Torino, Italy; **Noemi MANCENIDO**, Hospital Universitario Infanta Sofía, European University of Madrid, San Sebastián de los Reyes, Spain; **Miriam MAÑOSA**, Hospital Universitari Germans Trias i Pujol Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Badalona, Spain; **Maria Dolores MARTÍN-ARRANZ**, La Paz Institute for Health Research, La Paz Hospital, Madrid, Spain; **Laurianne PLASTARAS**, CHU Colmar, Colmar, France; **Maria Lia SCRIBANO**, Ospedale S. Camillo-Forlanini, Roma, Italy; **Subhasish SENGUPTA**, Our Lady of Lourdes Hospital, RCSI, Drogheda, Ireland; **Nils TEICH**, Internistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselerkrankheiten, Leipzig, Germany; **My-Linh TRAN-MINH**, Hôpital Saint-Louis, Université Paris Nord, Paris, France; **Evanthia ZAMPELI**, Alexandra General Hospital, Athens, Greece; **Leila AMIN-NEJAD**, Erasmus Hospital, VUB-ULB, Brussels, Belgium; **Teresa ARROYO**, Hospital Clínico Universitario "Lozano Blesa", Instituto de Investigación Sanitaria de Aragón (IIS-Aragón), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Zaragoza, Zaragoza, Spain; **Alain ATTAR**, Hôpital Beaujon, UFR de Médecine, Xavier Bichat, Université de Paris, Clichy la garenne, France; **Ann-Sofie BACKMAN**, Karolinska University Hospital, Inst Med Solna Karolinska Institutet, Stockholm, Sweden; **Anita BALINT**, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; **John BECKLY**, Royal Cornwall Hospital, University of Exeter Medical School, Truro, United Kingdom; **Shomron BEN HORIN**, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Sónia BERNARDO**, Centro Hospitalar Lisboa Norte, Lisboa, Portugal; **Ludovic CAILLO**, Hôpital universitaire de Nîmes, Université Montpellier-Nîmes, Nîmes, France; **Bénédicté CARON**, Department of Gastroenterology and Insemer NGERE U1256, Nancy University Hospital, University of Lorraine, 54500 Vandœuvre-lès-Nancy, France; **Maria Shanika DE SILVA**, Russells Hall Hospital, Dudley, United Kingdom; **Anna FABIÁN**, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; **Gionata FIORINO**, IRCCS S. Raffaele, Università Vita-Salute San Raffaele, Milano, Italy; **Ana GUTIERREZ**, Hospital General Universitario Alicante, Centro de Investigación Biomédica en Red de enfermedades Hepáticas y Digestivas - ISABIAL, Instituto de Investigación Sanitaria y Biomédica de Alicante, Alicante, Spain; **Adi LAHAT**, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Mohamed MASMOUDI**, Hôpital de Meaux, Meaux, France; **Marco MENDOLARO**,

Ospedale Ordine Mauriziano Umberto I, Università di Torino, Torino, Italy; **Vinciane MULS**, CHU Saint-Pierre, VUB-ULB, Brussels, Belgium; **Florian POULLENOT**, CHU Bordeaux, Université de Bordeaux, Pessac, France; **Christopher PROBERT**, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; **Catherine REENAERS**, CHU de Liège, ULiège, Liège, Belgium; **Mariann RUTKA**, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; **Zaman SARWARI**, Odense University Hospital Svendborg, University of Odense, Svendborg, Denmark; **Joanne SAYER**, Doncaster Royal Infirmary, Doncaster, United Kingdom; **Beatriz SICILIA**, Hospital Universitario de Burgos, Burgos, Spain; **Helena SOUSA**, Centro Hospitalar Universitário do Algarve - Portimão, Portimão, Portugal; **Catherine VAN KEMSEKE**, CHU de Liège, ULiège, Liège, Belgium; **Ana VIEIRA**, Hospital Garcia Orta, Almada, Portugal; **Yamile ZABANA**, Hospital Universitari Mútua Terrassa, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Terrassa, Spain; **Marco ASTEGIANO**, Ospedale San Giovanni antica sede, AOU Città della Salute e della Scienza di Torino, Torino, Italy; **Paul BANIM**, James Paget University Hospital, University of Suffolk, Great Yarmouth, United Kingdom; **Dominik BETTENWORTH**, Praxis für Innere Medizin, Münster, Germany; **Médina BOUALIT**, Hôpital de Valenciennes, Université de Lille, Valenciennes, France; **Jacob Broder BRODERSEN**, Hospital of Southwest Jutland, University of Southern Denmark, Esbjerg, Denmark; **Angeliki CHRISTIDOU**, Evangelismos General Hospital, Athens, Greece; **Rachel COONEY**, Queen Elizabeth Hospital, University of Birmingham, Birmingham, United Kingdom; **Jão CORTEZ PINTO**, Instituto Português Oncologia - Lisboa Francisco Gentil, Lisboa, Portugal; **Marília CRAVO**, Hospital Beatriz Ângelo, Loures, Portugal; **Anneline CREMER**, Erasmus Hospital, VUB-ULB, Brussels, Belgium; **Silvio DANESE**, IRCCS S. Raffaele, Università Vita-Salute San Raffaele, Milano, Italy; **Antonio DI SABATINO**, Policlinico San Matteo, Università di Pavia, Pavia, Italy; **Jan FALLINGBORG**, Aalborg University Hospital, University of Aalborg, Aalborg, Denmark; **Antonio FERRONATO**, Ospedale Alto Vicentino AULSS 7 Pedemontana, Santorso, Italy; **Esther GARCIA PLANELLA**, Hospital de la Santa Creu i Sant Pau, Open University of Catalonia, Barcelona, Spain; **Sanjay GUPTA**, Croydon University Hospital, St George's, University of London King's College School of Medicine and Dentistry, Croydon, United Kingdom; **Jonas HALVFARSON**, Örebro University Hospital, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; **Eran ISRAELI**, Wolfson Medical Center, Sackler Medical School Tel Aviv University, Tel Aviv, Israel; **Samantha KESTENBAUM**, Bristol Royal Infirmary, University of Bristol, Bristol, United Kingdom; **Lone LARSEN**, Aalborg University Hospital, University of Aalborg, Aalborg, Denmark; **Elisabeth MACKEN**, UZA, Antwerp University, Antwerp, Belgium; **Nicoletta MATHOU**, Konstantopoulou General Hospital, Athens, Greece; **Agnes MILASSIN**, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; **Joanna POFELSKI**, CH Ancey Genevois, Ancey, France; **Chiara RICCI**, Presidio Spedali Civili di Brescia, Università di Brescia, Brescia, Italy; **Francisco RODRIGUEZ-MORANTA**, Hospital Universitario de Bellvitge, IDIBELL, Hospitalet del Llobregat, Spain; **Martin SCHMIDT-LAUBER**, Praxis für Gastroenterologie Oldenburg, Oldenburg, Germany; **Ian SHAW**, Gloucester Royal Infirmary, Gloucester, United Kingdom; **Marta SOARES**, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal; **Heithem SOLIMAN**, Hôpital Louis Mourier, Université de Paris, Paris, France; **Christos TRIANTOS**, University Hospital of Patra, University of Patras, Patra, Greece; **Konstantinos ZOGRAFOS**, Athens Medical P. Fallon, Athens, Greece; **Anurag AGRAWAL**, Doncaster Royal Infirmary, Doncaster, United Kingdom; **Alessandro ARMUZZI**, IBD Center, Humanitas Research Hospital, Rozzano, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; **Alexandre AUBOURG**, CHU Trousseau Tours, Université de Tours, Tours, France; **Manuel BARREIRO-DE ACOSTA**, Hospital Clínico Universitario de Santiago de Compostela, University of Santiago de Compostela, Santiago, Spain; **Jesús BARRIO**, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León (SACYL), Valladolid, Spain; **Daniel BERGEMALM**, Örebro University Hospital, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; **Fernando BERMEJO**, Hospital Universitario de Fuenlabrada, University Rey Juan Carlos, Madrid, Spain; **Giorgia BODINI**, Ospedale San Martino, Università di Genova, Genova, Italy; **Johan BOHR**, Örebro University Hospital, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; **Peter BOSSUYT**, Imelda Hospital, Bonheiden, Belgium; **Dimitrios CHRISTODOULOU**, University Hospital of Ioannina, University of Ioannina, Ioannina, Greece; **Christophe CLAESSENS**, AZ Turnhout, Turnhout, Belgium; **Paul COLLINS**, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; **Ruth DE FRANCISCO**, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain; **Santiago GARCIA**, Hospital Universitario Miguel Servet, Zaragoza University, Zaragoza, Spain; **Sotirios GEORGIOPOULOS**, Athens Medical P. Fallon, Athens, Greece; **Felix GOUTORBE**, Centre Hospitalier de la Côte Basque, Bayonne, France; **Christos KALANTZIS**, Army Share Fund Hospital, Athens, Greece; **Anastasia KOURIKOU**, Hippokraton General Hospital, Athens, Greece; **Vincent MACE**, CHD Vendée, La Roche-sur-Yon, France; **Georgia MALAMUT**, Hôpital Européen Georges Pompidou, Université de Paris, Paris, France; **Paula MINISTRO**, Centro Hospitalar Tondela-Viseu, Viseu, Portugal; **Isabelle NION LARMURIER**, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; **Elena RICART**, Hospital Clinic Barcelona Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD) IDIBAPS, University of Barcelona (UB), Barcelona, Spain; **Mélanie SERRERO**, Hôpital Nord Marseille, Université d'Aix-Marseille, Marseille, France; **Juliette SHERIDAN**, St Vincent University Hospital &

University College Dublin, Dublin, Ireland; **Petra WEIMERS**, North Zealand Hospital, University of Copenhagen, Hillerød, Denmark; **Vibeke ANDERSEN**, Hospital of Southern Jutland, University of Southern Denmark, Aabenraa, Denmark; **Bruno ARROJA**, Hospital de Braga, Braga, Portugal; **Bernd BOKE-MEYER**, Gastroenterologische Gemeinschaftspraxis Minden, Minden, Germany; **Luis BUJANDA**, Hospital Universitario de Donostia, Biodonostia Health Research Institute, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of the Basque Country (UPV/EHU), San Sebastián, Spain; **Thibault DEGAND**, CHU Dijon, Dijon, France; **Carl ERIKSSON**, Örebro University Hospital, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; **Cécile GARCEAU**, CHD Vendée, La Roche-sur-Yon, France; **Henning GLERUP**, Regional Hospital Silkeborg, University of Aarhus, Silkeborg, Denmark; **Idan GOREN**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Lucina JACKSON**, Bon Secours Hospital, UCC, Cork, Ireland; **Stéphane KOCH**, CHU Besançon, Université Besançon, Franche-comté, France; **Francisco MESONERO**, Hospital Universitario Ramón y Cajal, University of Alcalá de Henares, Madrid, Spain; **Ingrid ORDAS**, Hospital Clinic of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EHD), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Barcelona, Spain; **Pauline RIVIERE**, CHU Bordeaux, Université de Bordeaux, Pessac, France; **Simone SAIBENI**, Ospedale di Rho, Rho, Italy; **João SOARES**, Hospital de Braga, Braga, Portugal; **Noémie TAVERNIER**, Hôpital Tourcoing, Université de Lille, Tourcoing, France; **Klaus THEEDE**, Hvidovre hospital, University of Copenhagen, Hvidovre, Denmark; **Bella UNGAR**, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Eike BÄSTLEIN**, Magen Darm Zentrum Wiener Platz, Köln, Germany; **Antonio GASBARRINI**, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Italy; **Andreas PROTOPAPAS**, AHEPA University Hospital, Thessaloniki, Greece; **Wolfgang REINDL**, Universitätsmedizin Mannheim, Universitätsmedizin Mannheim, Mannheim, Germany; **Fabrizio BOSSA**, Fondazione Casa Solliello della Sofferenza, IRCCS, San Giovanni Rotondo, Italy; **Ailsa HART**, St Marks Hospital, Imperial College London, London, United Kingdom; **Franz-Josef HEIL**, Fachärztliche Schwerpunktpraxis für Magen-Darm-Erkrankungen, Andernach, Germany; **Anthony O'CONNOR**, TUH, TCD, Dublin, Ireland; **Bas OLDENBURG**, UMC Utrecht, Utrecht University, Utrecht, The Netherlands; **Luca PASTORELLI**, Policlinico San Donato, Università di Milano, San Donato Milanese, Italy; **Stephen PATCHETT**, Beaumont Hospital, RCSI, Dublin, Ireland; **Subramaniam RAMAKRISHNAN**, Warrington Hospital, Warrington, United Kingdom; **John De CAESTECKER**, Leicester Royal Infirmary, Leicester University, Leicester, United Kingdom; **Ana ECHARRI**, Hospital ArquíStudy Coordinatorto Marcid, Complejo Hospitalario Universitario de Ferrol, University of Navarra, Ferrol, Spain; **David KEVANS**, St. James's Hospital, TCD, Dublin, Ireland; **Jürgen BÜNING**, Schwerpunktpraxis Gastroenterologie, Lübeck, Germany; **Rosa COELHO**, Centro Hospitalar Universitário de São João, Faculty of Medicine of the University of Porto, Porto, Portugal; **Jeroen JANSEN**, OLVG oost, Amsterdam, The Netherlands; **Benjamin KOSLOWSKI**, Shaare Tzedek Medical Center, Hebrew University, Jerusalem, Israel; **Christopher WELLS**, University Hospital of North Tees, Stockton, United Kingdom; **Daniel CEBALLOS**, Hospital Universitario de Gran Canaria Dr. Negrín, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain; **Daan De Konig**, Gelre ziekenhuizen, Gelre, The Netherlands; **Ingrid KÖNIG**, Praxis Hospital, Bautzen, Germany; **Hari PADMANABHAN**, Newcross Hospital, Wolverhampton, United Kingdom; **Timi PATANI**, Warrington Hospital, Warrington, United Kingdom; **Raheel QURESHI**, Queen Elizabeth Hospital, Newcastle University Medical School, Gateshead, United Kingdom; **Edyta ZAGOROWICZ**, The Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland; **Matthieu ALLEZ**, Hôpital Saint-Louis, Université Paris Nord, Paris, France; **Emmanuel ARCHAVLIS**, Evangelismos General Hospital, Athens, Greece; **Delphine BONNET**, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; **Luisa GUIDI**, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Roma, Italy; **Deirdre McNAMARA**, TUH, TCD, Dublin, Ireland; **Piero VERNIA**, Policlinico Umberto I, Università La Sapienza, Roma, Italy; **Michael WEIDENHILLER**, Facharztzentrum Regensburg, Regensburg, Germany; **Lang ALON**, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Trine BOYSEN**, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark; **Charlotte DELATTRE**, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; **Richard FARRELL**, Connolly Hospital, RCSI, Dublin, Ireland; **Rolf-Achim KRÜGER**, Praxengemeinschaft, Radebeul, Germany; **Thierry PAUPARD**, CH Dunkerque, Dunkerque, France; **Bénédicte PROST**, CH Saint-Joseph Saint-Luc, Lyon, France; **Ida VIND**, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark; **Flavio CAPRIOLI**, Ospedale Maggiore Policlinico di Milano, Università di Milano, Milano, Italy; **Vladimir GANCHO**, Nykøbing Falster Sygehus, University of Copenhagen, Nykøbing Falster, Denmark; **Vincent QUENTIN**, Hôpital Yves Le Foll, Saint-Brieuc, France; **Benjamin AVIDAN**, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Geert D'HAENS**, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands; **Jane MCCARTHY**, Mercy University Hospital, UCC, Cork, Ireland; **Jonathan SNOOK**, Poole Hospital, Poole, United Kingdom; **Konstantinos SOUFLERIS**, Theagenelo Cancer Hospital, Thessaloniki, Greece; **Frank ZERBIB**, CHU Bordeaux, Université de Bordeaux, Pessac, France; **Dan CARTER**, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Annekatrien DEPLA**, Slotervaart ziekenhuis, Amsterdam, The Netherlands; **Thomas EISENBACH**, Praxengemeinschaft, Leverkusen, Germany; **Walter FRILES**, Policlinico G. Martino, Università di Messina, Messina, Italy; **Nikolaos GRAMMATIKOS**, Hippokraton General Hospital, Thessaloniki,

Greece; **Saskia ILEGEMS**, Emmaüs ziekenhuis, AZ St-Maarten, Mechelen, Belgium; **Antonio LOPEZ-SANROMAN**, Hospital Universitario Ramón y Cajal, University of Alcalá de Henares, Madrid, Spain; **Jacques MOREAU**, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; **Gabriele RIEGLER**, Azienda ospedaliera Seconda Università di Napoli, Seconda Università di Napoli, Napoli, Italy; **Svend RIETDIJK**, OLVG oost, Amsterdam, The Netherlands; **Marta ROCHA**, Centro Hospitalar do Porto, Porto, Portugal; **Isabelle ROSA**, Centre hospitalier intercommunal de Créteil, Créteil, France; **Barbara RYAN**, TUH, TCD, Dublin, Ireland; **Yelena YEREMENKO**, Haemeq Medical Center, Faculty of Medicine Technion, Afula, Israel; **Arnaud BORUCHOWICZ**, Hôpital de Valenciennes, Université de Lille, Valenciennes, France; **Filipe DAMIÃO**, Centro Hospitalar Lisboa Norte, Lisboa, Portugal; **Foteini LAOUDI**, Athens Medical P. Faliro, Athens, Greece; **Andreas LÜGERING**, MVZ Portal 10, Münster, Germany; **Giampiero MACARRI**, Ospedale civile Augusto Murri, Fermo, Italy; **Konstantinos THOMOPOULOS**, University Hospital of Patra, University of Patras, Patra, Greece; **Luisa BARROS**, Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal; **Thomas BLIXT**, Zealand University Hospital, University of Copenhagen, Koege, Denmark; **Aurélien GARROS**, CH Saint-Joseph Saint-Luc, Lyon, France; **Sam KHORRAMI**, Hospital Universitario Son Espases, Palma de Mallorca, Spain; **Harry SOKOL**, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; **Andreas STURM**, DRK-Kliniken Berlin, DRK-Kliniken Berlin, Berlin, Germany; **Dan LIVOVSKY**, Shaare Tzedek Medical Center, Hebrew University, Jerusalem, Israel; **Jochen MAUL**, MVZ für Gastroenterologie am Bayrischen Platz, Berlin, Germany; **Heinrich MIKS**, MVZ Hamm, Hamm, Germany; **Vasilios PAPAPOPOULOS**, Attikon University Hospital, Athens, Greece; **Carsten SCHMIDT**, Medizinische Klinik Fulda, Medizinische Klinik Fulda, Fulda, Germany; **Yifat SNIR**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Lise SVENNINGSEN**, Regional Hospital Herring, University of Aarhus, Herring, Denmark; **Wafaa AHMED**, Maidstone Hospital, Maidstone, United Kingdom; **Yelena BROITMAN**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Emmanuel CUILLERIER**, Hôpital Victor Jousselin, Dreux, France; **Prashant KANT**, York Hospital, Hull York Medical School, York, United Kingdom; **Jan LEYDEN**, MMUH, UCD, Dublin, Ireland; **Lev LICHTENSTEIN**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Susana LOPES**, Centro Hospitalar Universitário de São João, Faculty of Medicine of the University of Porto, Porto, Portugal; **Chloé MARTINEAU**, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; **Hugh MULCAHY**, St Vincent University Hospital & University College Dublin, Dublin, Ireland; **Axel SCHWEITZER**, Gastroenterologische Gemeinschaftspraxis Münster, Münster, Germany; **Fiona VAN SCHAİK**, UMC Utrecht, Utrecht University, Utrecht, The Netherlands; **Hagar BANAI**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Pauline DANION**, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; **Charlotte DULERY**, CHU Bordeaux, Université de Bordeaux, Pessac, France; **Herma FIDDER**, UMC Utrecht, Utrecht University, Utrecht, The Netherlands; **Claire GAY**, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; **Hervé HAGEGE**, Centre hospitalier intercommunal de Créteil, Créteil, France; **Florence HARNOIS**, CH Marne la vallée, Jossigny, France; **Søren Peter JØRGENSEN**, Aarhus University Hospital, University of Aarhus, Aarhus, Denmark; **Jens MÜLLER-ZIEHM**, Gastroenterologische Schwerpunktpraxis Hannover, Hannover, Germany; **Michail OIKONOMOU**, Euroclinic, Athens, Greece; **Carolina PALMELA**, Hospital Beatriz Ângelo, Loures, Portugal; **Jörg SCHULZE/RÖSKE**, Berufsärztliche Gemeinschaft, Jerichow, Germany; **Mark SMITH**, Royal Shrewsbury Hospital, Keele University School of Medicine, Staffordshire University, Shrewsbury, United Kingdom; **Tamar THURM**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Francesca BRESSO**, Karolinska University Hospital, Inst Med Solna Karolinska Institutet, Stockholm, Sweden; **Hedia BRIXI**, CHU de Reims, Université de Reims Champagne Ardenne, Reims, France; **John JONES**, Royal Shrewsbury Hospital, Keele University School of Medicine, Staffordshire University, Shrewsbury, United Kingdom; **Padraig MACMATHUNA**, MMUH, UCD, Dublin, Ireland; **Spyridon MICHPOPOULOS**, Alexandra General Hospital, Athens, Greece; **Claire PAIN-CHART**, Hôpital de Valenciennes, Université de Lille, Valenciennes, France; **Yulia RON**, Sourasky Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Marianne VESTER-ANDERSEN**, Zealand University Hospital, University of Copenhagen, Koege, Denmark; **Gonçalo ALEXANDRINO**, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal; **Norbert BÖRNER**, Gastroenterologische Gemeinschaftspraxis Mainz, Mainz, Germany; **Mariana CARDOSO**, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal; **Cristina CHAGAS**, Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal; **Axel DIGNAß**, Agaplesion Krankenhaus Frankfurt, Agaplesion Krankenhaus Frankfurt, Frankfurt, Germany; **Iris DOTAN**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Charlotte HEDIN**, Karolinska University Hospital, Inst Med Solna Karolinska Institutet, Stockholm, Sweden; **Pantelis KARATZAS**, Laiko General Hospital, Athens, Greece; **Panagiotis KASAPIDIS**, Central Clinic, Athens, Greece; **Károly PALATKA**, 2nd Department of Internal Medicine, University of Debrecen, Debrecen, Hungary; **Georgios SAKIZLIS**, Latriko Athinon Hospital, Athens, Greece; **Ana WILSON**, St Marks Hospital, Imperial College London, London, United Kingdom; **Nick BOSANKO**, NHS Plymouth, Plymouth, United Kingdom; **Paulo CALDEIRA**, Centro Hospitalar Universitário do Algarve - Faro, Faro, Portugal; **Charlotte GAGNIERE**, Hôpital Henri Mondor, Université de Paris, Paris, France; **Louise LIBIER**, Hôpital Tourcoing, Université de Lille, Tourcoing, France; **Camille MEUNIER**, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; **Gero MOOG**, Gastroenterologische Facharztpraxis, Kassel, Germany; **Audrey PASQUION**, CH Saint-Joseph Saint-Luc, Lyon, France; **Roberta PICA**, Ospedale Sandro Pertini, Roma, Italy; **Ayesha AKBAR**, St Marks Hospital,

Imperial College London, London, United Kingdom; **Nadia ARAB**, Hôpital L'archet, Nice, France; **Gillaume CADIOT**, CHU de Reims, Université de Reims Champagne Ardenne, Reims, France; **João CARVALHO**, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal; **Claire CHARPIGNON**, Institut Mutualiste Montsouris, Paris, France; **Klaus FELLERMANN**, Praxisklinik Nürnberg, Praxisklinik Nürnberg, Freudenstadt, Germany; **Sigal FISHMAN**, Sourasky Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Gerald FRASER**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Nathan GLUCK**, Sourasky Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Mark HOESL**, Praxisklinik Nürnberg, Nürnberg, Germany; **Jaroslav KIERKUS**, Children's Memorial Health Institute, Warsaw, Poland; **Maria KLOPOCKA**, Nicolaus Copernicus University in Toruń, Collegium Medicum, Bydgoszcz, Poland; **Eduardo MARTIN ARRANZ**, Hospital Universitario La Paz, Instituto de Investigación Sanitaria La Paz (IDIPAZ), Madrid, Spain; **Luis MENCHEN**, Hospital Universitario Gregorio Marañón, IISGM, Complutense University of Madrid, Madrid, Spain; **Susanna NIKOLAUS**, Universitätsklinikum Schleswig-Holstein, United KingdomSH Kiel, Kiel, Germany; **Anca PETRACHE**, Vejle Hospital, University of Odense, Vejle, Denmark; **Cyriel PONSIOEN**, Amsterdam UMC Location AMC, Amsterdam, The Netherlands; **Sabino RIESTRA**, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), University of Oviedo, Oviedo, Spain; **Pilar ROBLEDO**, Hospital Universitario de Cáceres, University of Extremadura, Cáceres, Spain; **Cristina RODRIGUEZ**, Complejo Hospitalario de Navarra, Public University of Navarra, Pamplona, Spain; **Misheal SAMER**, Haemeq Medical Center, Faculty of Medicine Technion, Afula, Israel; **Matthias TISCHER**, Gastroenterologische Praxis Dresden, Dresden, Germany; **Joanna WYPYCH**, Copernicus Hospital, Gdańsk, Poland; **Julien BAUDON**, Centre Hospitalier de Cholet, Cholet, France; **Cristina BEZZIO**, Ospedale di Rho, Rho, Italy; **Gilles BOSCHETTI**, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; **Johan BURISCH**, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark; **Tom CREED**, Bristol Royal Infirmary, University of Bristol, Bristol, United Kingdom; **Maria Giulia DEMARZO**, Azienda ospedaliera universitaria San Martino, Università di Genova, Genova, Italy; **Stefano FESTA**, Ospedale San Filippo Neri, Roma, Italy; **Andrés FIGUEROA**, Hospital Universitario de Gran Canaria Dr. Negrín, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain; **Mette JULSGAARD**, Aarhus University Hospital, University of Aarhus, Aarhus, Denmark; **Pablo NAVARRO**, Hospital Clínico Universitario de Valencia, University of Valencia, Valencia, Spain; **Pablo PEREZ-GALINDO**, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain; **Cléa ROUILLON**, CHU Caen, Université de Caen, Caen, France; **Emanuele SABLICH**, Ospedale di Rho, Rho, Italy; **Joan TOSCA**, Hospital Clínico Universitario de Valencia, University of Valencia, Valencia, Spain; **Mathias VIDON**, CHU Trousseau Tours, Créteil, France; **Marine VIDON**, CHRU Nancy, Université de Nancy, Nancy, France; **René-Louis VITTE**, Centre Hospitalier Poissy St Germain-en-Laye, St Germain-en-Laye, France; **Anne WAMPACH**, Centre hospitalier intercommunal de Créteil, Créteil, France

**National Coordinators:** **Vered ABITBOL**, Hôpital Cochin AP-AH, Université Paris Cité, Paris, France; **Sebastian SHAJI**, Hull University Teaching Hospitals – Hull York Medical School, University of Hull, Hull, United Kingdom; **Livia BIANCONI**, Policlinico Tor Vergata, Università di Roma Tor Vergata, Roma, Italy; **Alessandro ARMUZZI**, IBD Center, Humanitas Research Hospital, Rozzano, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; **Konstantinos KARMIRIS**, Venizeleio General Hospital, Heraklion, Greece; **Nikolaos VIAZIS**, Evangelismos General Hospital, Athens, Greece; **Eugeni DOMENECH**, Hospital Universitari Germans Trias i Pujol Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat Autònoma Barcelona, Badalona, Spain; **Javier P. GISBERT**, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universidad Autónoma de Madrid (UAM), Madrid, Spain; **Peter BOSSUYT**, Imelda General Hospital, Bonheiden, Belgium; **Catherine REENAERS**, CHU de Liège, ULiège, Liège, Belgium; **Christian MAASER**, Lüneburg Clinic, Lüneburg, Germany; **Britta SIEGMUND**, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; **Ulf HELWIG**, Private Practice for Internal Medicine, University of Kiel, Germany; **Johan BURISCH**, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark; **Mette JULSGAARD**, Aarhus University Hospital, University of Aarhus, Aarhus, Denmark; **Henit YANAI**, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; **Uri KOPYLOW**, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Glen DOHERTY**, St Vincent University Hospital & University College Dublin, Dublin, Ireland; **Fernando MAGRO**, Centro Hospitalar Universitário de São João, Faculdade de Medicina da Universidade do Porto, Porto, Portugal; **Tamás MOLNAR**, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; **Mark LÖWENBERG**, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands; **Bas OLDENBURG**, UMC Utrecht, Utrecht University, Utrecht, The Netherlands; **Jonas HALFVARSON**, Örebro University Hospital, Faculty of Medicine and Health of Örebro University, Örebro, Sweden; **Ann-Sofie BACKMAN**, Karolinska University Hospital, Inst Med Solna Karolinska Institutet, Stockholm, Sweden; **Edyta ZAGOROWICZ**, The Maria Skłodowska-Curie

National Research Institute of Oncology, Warsaw, Poland; **Jaroslav KIERKUS**, Children's Memorial Health Institute, Warsaw, Poland.

**Methodologists/Biostatisticians/Data Managers:** **Cédric BAUMANN**, UMDS CHRU Nancy – Hôpitaux de Brabois, Vandoeuvre-Les-Nancy, France; **Isabelle CLERC URMES**, UMDS CHRU Nancy – Hôpitaux de Brabois, Vandoeuvre-Les-Nancy, France; **Hélène ROUSSEAU**, UMDS CHRU Nancy – Hôpitaux de Brabois, Vandoeuvre-Les-Nancy, France; **Marc BORIE**, UMDS CHRU Nancy – Hôpitaux de Brabois, Vandoeuvre-Les-Nancy, France.

**Coders:** **Bénédicte CARON**, Department of Gastroenterology and Inserm NGERE U1256, Nancy University Hospital, University of Lorraine, 54500 Vandoeuvre-lès-Nancy, France; **Julien KIRCHGESNER**, Hôpital Saint-Antoine, Sorbonne Université, Paris, France; **Mathieu UZZAN**, Hôpital Henri Mondor, Université Paris Est, Créteil, France; **Rachel COONEY**, Queen Elizabeth Hospital, University Of Birmingham, Birmingham, United Kingdom; **Kelly CHATTEN**, Fairfield General Infirmary, Oldham, United Kingdom; **Jimmy LIMDI**, Northern Care Alliance NHS Foundation Trust, University of Manchester, Manchester, United Kingdom; **Peter RIMMER**, Queen Elizabeth Hospital, University Of Birmingham, Birmingham, United Kingdom; **Iqbal TARIQ**, Queen Elizabeth Hospital, University Of Birmingham, Birmingham, United Kingdom; **Marta COSSIGNANI**, Policlinico Tor Vergata, Università Di Roma Tor Vergata, Roma, Italy; **Nikolaos VIAZIS**, Evangelismos General Hospital, Athens Greece; **Fiorella CAÑETE**, Hospital Universitari Germans Trias i Pujol Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Badalona, Spain; **Tom HOLVOET**, Bird Group, Landegem, Belgium; **Susanne KRASZ**, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; **Petra WEIMERS**, North Zealand Hospital, University Of Copenhagen, Hillerød, Denmark; **Idan GOREN**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Juliette SHERIDAN**, St Vincent University Hospital & University College Dublin, Dublin, Ireland; **Sandra DIAS**, Grupo De Estudo Da Doença Inflamatória Intestinal – GEDII, Porto, Portugal; **Klaudia FARKAS**, Albert Szent-Györgyi Health Center, University Of Szeged, Szeged, Hungary; **Daniel BERGEMALM**, Örebro University Hospital, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; **Edyta ZAGOROWICZ**, The Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

**Study Coordinators:** **Hadas ABALIA**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Aziza ABAZA**, Hôpital de Meaux, Meaux, France; **Gai ABRAMOVICH**, Haemeq Medical Center, Faculty of Medicine Technion, Afula, Israel; **Ingrid ACKZELL**, Karolinska University Hospital, Stockholm, Sweden; **Carol ADAMS**, University Hospital of North Tees, Stockton, United Kingdom; **Catherine ADLETON**, Royal Derby Hospitals, Derby, United Kingdom; **Erika ALFAMBRA**, Hospital Clínico Universitario "Lozano Blesa", Instituto de Investigación Sanitaria de Aragón (IIS-Aragón), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Zaragoza, Spain; **Alicia ALGABA**, Hospital Universitario de Fuenlabrada, University Rey Juan Carlos, Madrid, Spain; **Clare ALLCOCK**, Russells Hall Hospital, Dudley, United Kingdom; **Joanna ALLISON**, Yeovil District Hospital, Yeovil, United Kingdom; **Karine AMOURIAUX**, CHU Nantes, Université de Nantes, Nantes, France; **Julie ANDERSON**, York Hospital, Hull York Medical School, York, United Kingdom; **Emma ANDERSON**, Our Lady of Lourdes Hospital, RCSI, Drogheda, Ireland; **Saskia APPELMANS**, BIRD GROUPE, Landegem, Belgium; **Sophie ARMAND**, CH Saint-Joseph Saint-Luc, Lyon, France; **Lisa ARMSTRONG**, Airedale General Hospital, Leeds University School of Medicine, Airedale, United Kingdom; **Stacey ATKINS**, Torbay Hospital, Torquay, United Kingdom; **Masoumeh ATTARAN-BANDARABADI**, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; **Yvonne BAILEY**, TUH, TCD, Dublin, Ireland; **Florian BÄR**, Schwerpunktpraxis Gastroenterologie, Lübeck, Germany; **Stephanie BARDOT**, CHU Nantes, Université de Nantes, Nantes, France; **Natasha BECK**, Bristol Royal Infirmary, University of Bristol, Bristol, United Kingdom; **Lillie BENNETT**, Queen Elizabeth Hospital, University of Birmingham, Birmingham, United Kingdom; **Jonathan Phil BERGFELD**, Medizinische Klinik Fulda, Medizinische Klinik Fulda, Fulda, Germany; **Ram-dane BERKANE**, Hôpital de Meaux, Meaux, France; **Marion BLIN**, Hôpital Nord Marseille, Université Aix-Marseille, Marseille, France; **Hanne BOEY**, Imelda Hospital, Bonheiden, Belgium; **Louise BOWLAS**, Queen Elizabeth Hospital, University of Birmingham, Birmingham, United Kingdom; **Joanne BRADLEY-POTTS**, Wythenshawe Hospital, University of Manchester, Manchester, United Kingdom; **Tracy BREAR**, King's Mill Hospital, University of Nottingham, Sutton-in-Ashfield, United Kingdom; **Nicole BRETLANDER-PETERS**, MVZ Hamm, Hamm, Germany; **Ellen BROWN**, Darlington Memorial Hospital, Durham, United Kingdom; **Johanna BROWN**, Royal Derby Hospitals, Derby, United Kingdom; **Elizabeth BUCKINGHAM**, Royal Shrewsbury Hospital, Keele University School of Medicine, Staffordshire University, Shrewsbury, United Kingdom; **Katrien BUELLENS**, Emmaüs ziekenhuis, AZ St-Maarten, Mechelen, Belgium; **Rhian BULL**, Chelsea and Westminster Hospital, Imperial College London, London, United Kingdom; **Maura BURKE**, UCHG, NUIG, Galway, Ireland; **Leighanne BURNS**, University Hospital Coventry, University of Warwick, Coventry, United Kingdom; **Julie BURTON**, Pinderfields Hospital, Wakefield, United Kingdom; **Agness BWALYA**, Harrogate District Hospital, Harrogate, United Kingdom; **Karine CABANAS**, CHU Nantes, Université de Nantes, Nantes, France; **Muriel CALLAGHAN**, Connolly



Hospital, RCSI, Dublin, Ireland; **Océane CAMOU**, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; **Debbie CAMPBELL**, Colchester General Hospital, Barts and The London School of Medicine and Dentistry, Norwich Medical School, Anglia Ruskin University, Colchester, United Kingdom; **Elvira CAPOFERRO**, Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Italy; **Mandy CARNAHAN**, Royal Shrewsbury Hospital, Keele University School of Medicine, Staffordshire University, Shrewsbury, United Kingdom; **Cornelia CARNIO**, Universitätsklinikum Erlangen, Universitätsklinikum Erlangen, Erlangen, Germany; **Anne CARTER**, Royal Shrewsbury Hospital, Keele University School of Medicine, Staffordshire University, Shrewsbury, United Kingdom; **Concetta CASALI CLACK**, MVZ for Gastroenterology at Bayrischer Platz, Berlin, Germany; **Leïla CHEDOUBA**, Hôpital Saint-Louis, Université Paris Nord, Paris, France; **Bessie CIPRIANO**, St Bartholomew's Hospital, Queen Mary University of London, London, United Kingdom; **Sophie CLAEYS**, AZ St-Lucas, Ghent, Belgium; **Elizabeth CLAYTON**, Pinderfields Hospital, Wakefield, United Kingdom; **Manon CLOSSET**, CHRU Nancy, Université de Nancy, Nancy, France; **Dilek COBAN**, CHU Clermont-Ferrand, Inserm U1071, M2ISH, Université Clermont Auvergne, Clermont-Ferrand, France; **Sara COCCOCIA**, Policlinico San Matteo, Pavia University, Pavia, Italy; **Carolann COE**, St Vincent University Hospital & University College Dublin, Dublin, Ireland; **Helen COLE**, Royal Devon and Exeter Hospital, University of Exeter Medical School, Exeter, United Kingdom; **Emilie COLLET**, CHU Namur, Site Godinne, University of Namur, Namur, Belgium; **Kayleigh COLLINS**, Gloucester Royal Infirmary, Gloucester, United Kingdom; **Isabelle COMBES**, CH Annecy Genevois, Annecy, France; **Emma CONNOR**, Nottingham University Hospitals NHS Trust Queen's Medical Centre, Nottingham, United Kingdom; **Kathryn CONSTANTIN**, Watford General Hospital, Watford, United Kingdom; **Susan COOKE**, Chesterfield Royal Hospital, Chesterfield, United Kingdom; **Nathanaëlle CORNET**, CHU Angers, Angers, France; **Estelle CORRIHONS**, Centre Hospitalier de la Côte Basque, Bayonne, France; **Pilar CORSINO**, Hospital Universitario Miguel Servet, Zaragoza, Zaragoza University, Zaragoza, Spain; **Rosie CORTAVILLE**, Watford General Hospital, Watford, United Kingdom; **Marta COSSIGNANI**, Policlinico Tor Vergata, Università di Roma Tor Vergata, Roma, Italy; **Donna COTTERILL**, Weston General Hospital, Weston-Super-Mare, United Kingdom; **Amanda COWTON**, Darlington Memorial Hospital, Durham, United Kingdom; **Harriet COX**, York Hospital, Hull York Medical School, York, United Kingdom; **Viktoria CRIPPS**, Musgrove Park Hospital, Taunton, United Kingdom; **Amanda CROWDER**, Chesterfield Royal Hospital, Chesterfield, United Kingdom; **Tzufit CUKIER**, Shaare Tzedek Medical Center, Hebrew University, Jerusalem, Israel; **Amelia DANIEL**, Princess Alexandra Hospital, Harlow, United Kingdom; **Chris DAWE**, Royal Bolton Hospital, Bolton, United Kingdom; **Jose DE HAAN**, Gelre ziekenhuizen, Gelre, The Netherlands; **Rosanna DE LA CROIX**, OLVG oost, Amsterdam, The Netherlands, Lier DECAESTEKER, AZ Delta, campus Rumbek, Roeselare, Belgium; **Evva DEJONCKHEERE**, AZ Delta, campus Rumbek, Roeselare, Belgium; **Juan DELARE VILLANEGRO**, Addenbrookes's Hospital, University of Cambridge, Cambridge, United Kingdom; **Guillaume DELAVAL**, CHU Caen, Université de Caen, Caen, France; **Mariangela DELLIPONTI**, Policlinico San Matteo, Pavia University, Pavia, Italy; **Aude DELOMMEZ**, CHU Lille, Université de Lille, Lille, France; **Emilie DETRY**, CHRU Nancy, Université de Nancy, Nancy, France; **Melanie DHANARATNE**, Ealing Hospital, Imperial College London, London, United Kingdom; **Sandra DIAS**, Grupo de Estudo da Doença Inflamatória Intestinal GEDI, Porto, Portugal; **Laura DIEZ GALAN**, Hospital Universitario Miguel Servet, Zaragoza, Zaragoza University, Zaragoza, Spain; **Marie DODEL**, CHU Clermont-Ferrand, Inserm U1071, M2ISH, Université Clermont Auvergne, Clermont-Ferrand, France; **Emma DOOKS**, Airedale General Hospital, Leeds University School of Medicine, Airedale, United Kingdom; **Joseph DU CHEYRON**, Centre Hospitalier Poissy St Germain-en-Laye, St Germain-en-Laye, France; **Linda DUANE**, UCHG, NUIG, Galway, Ireland; **Helene Dukwen**, Internistische Praxengemeinschaft Oldenburg, Kiel University, Oldenburg, Germany; **Jennifer DULLING VULGO COCHRAN**, MVZ for Gastroenterology at Bayrischer Platz, Berlin, Germany; **Simona DYER**, Scarborough Hospital, Hull York Medical School, Scarborough, United Kingdom; **Harvey DYMOND**, Weston General Hospital, Weston-Super-Mare, United Kingdom; **Charlotte EKBLAD**, Royal United Hospitals Bath, Bath, United Kingdom; **Kerry ELLIOTT**, Scarborough Hospital, Hull York Medical School, Scarborough, United Kingdom; **Ingrid EMMERSON**, South Tyneside District Hospital, South Shields, United Kingdom; **Irène EUGENE-JOLCHINE**, Centre Hospitalier Poissy St Germain-en-Laye, St Germain-en-Laye, France; **Lorna FLEMING**, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; **Lorna FLEMING**, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; **Eve FLETCHER**, Royal Cornwall Hospital, University of Exeter Medical School, Truro, United Kingdom; **Sarah FORD**, Hull University Teaching Hospitals, Hull York Medical School/ University of Hull, Hull, United Kingdom; **Greg FORSHAW**, York Hospital, Hull York Medical School, York, United Kingdom; **Angela FOULD**, Torbay Hospital, Torquay, United Kingdom; **Caroline FRANCOIS**, Centre Hospitalier de CHOLET, Cholet, France; **Nicole FUGE**, Klinikum Lüneburg, Klinikum Lüneburg, Lüneburg, Germany; **Gal GAFNI**, Hameeq Medical Center, Faculty of Medicine Technion, Afula, Israel; **Miri GANON**, Wolfson Medical Center, Sackler Medical School Tel Aviv University, Tel Aviv, Israel; **Olga GARCIA NUÑEZ**, Hospital Universitario Gregorio Marañón, Madrid, Spain; **Laura GARCIA RAMIREZ**, Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP), Madrid, Spain; **Sophie GELDER**, Queen Elizabeth Hospital, Gateshead, United Kingdom; **Raimonda GETT-KOWSKI**, Competence Network for Intestinal Diseases e.V., Kiel, Germany; **Daniela GILARDI**, Istituto clinico Humanitas, Rozzano, Italy; **Paolo GIUFFRIDA**, Policlinico San Matteo, Pavia University, Pavia, Italy; **Vincent GOBERT**, Hôpital de Meaux, Meaux, France; **Jo GODDEN**, West Suffolk Hospital, University of Suffolk, Suffolk, United Kingdom; **Nuala GODWIN**, Beaumont Hospital, RCSI, Dublin, Ireland; **Kay GOULDEN**, Fairfield General Infirmary, Oldham, United Kingdom; **Sharon GRAHAM**, Ulster Hospital, Belfast, United Kingdom; **Charlotte GREEN**, Barnsley General Hospital, University of Sheffield, Barnsley, United Kingdom; **Marie GREEN**, Newcross Hospital, Wolverhampton, United Kingdom; **Aboubakar GUEYE**, Groupe Hospitalier Bichat-Claude Bernard, Paris, France; **Tuba GULER**, Schwerpunktpraxis Gastroenterologie, Lübeck, Germany; **Ida GUSTAVSSON**, Örebro University Hospital, Örebro, Sweden; **Helena HADJISAVVAS**, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; **Fiona HAMMONDS**, Royal Cornwall Hospital, University of Exeter Medical School, Truro, United Kingdom; **Christina HANTZI**, Agaplesion Krankenhaus Frankfurt, Agaplesion Krankenhaus Frankfurt, Frankfurt, Germany; **Marion HAUKE**, Universitätsmedizin Mannheim, Universitätsmedizin Mannheim, Mannheim, Germany; **Julie HAYDOCK**, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; **Julie HAYDOCK**, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; **Oria HAYES**, St. James's Hospital, TCD, Dublin, Ireland; **Lizette HELBO NISLEV**, North Zealand Hospital, University of Copenhagen, Hillerød, Denmark; **Jessica HOCHSTODTER**, Competence Network for Intestinal Diseases e.V., Kiel, Germany; **Ashleigh HOGG**, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, United Kingdom; **Ashleigh HOGG**, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, United Kingdom; **Manuela HÖLBING**, Medizinische Klinik Fulda, Medizinische Klinik Fulda, Fulda, Germany; **Maureen HOLLAND**, Macclesfield District General Hospital, Macclesfield, United Kingdom; **Maartje HOLSBERGEN**, Amsterdam University Medical Center, location AMC, Amsterdam, The Netherlands; **Linda HOWARD**, Yeovil District Hospital, Yeovil, United Kingdom; **Aviya HOYDA**, Shaare Tzedek Medical Center, Hebrew University, Jerusalem, Israel; **Robert HULL**, Royal Bolton Hospital, Bolton, United Kingdom; **Jane IRISH**, St Bartholomew's Hospital, Queen Mary University of London, London, United Kingdom; **Wendy JACKSON**, James Cook University Hospital, Durham University, Newcastle University, Middlesbrough, United Kingdom; **Wendy JANSSEN**, AZ Turnhout, Turnhout, Belgium; **Lesley JEFFREY**, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, United Kingdom; **Lesley JEFFREY**, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, United Kingdom; **Sofia JOURDAN**, CHU Dijon, Dijon, France; **Izabela JUTROWSKA**, Medical Network, Warsaw, Poland; **Chava KANIEL**, Shaare Tzedek Medical Center, Hebrew University, Jerusalem, Israel; **Theofilos KAREZOS**, EOMIFNE (Greek IBD Club), Athens, Greece; **Niamh KELLY**, Bon Secours, UCC, Cork, Ireland; **Jessica KELLY**, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; **Mary KENNEDY**, Connolly Hospital, RCSI, Dublin, Ireland; **Una KENNEDY**, St. James's Hospital, TCD, Dublin, Ireland; **Joyce KIBARU**, St George's Hospital, University of London, London, United Kingdom; **Gemma KIRKMAN**, Doncaster Royal Infirmary, Doncaster, United Kingdom; **Janine KLAPROTH**, Klinikum Lüneburg, Klinikum Lüneburg, Lüneburg, Germany; **Corinna KNEESE**, Schwerpunktpraxis Gastroenterologie, Lübeck, Germany; **Andrea KOCH**, Competence Network for Intestinal Diseases e.V., Kiel, Germany; **Kathleen KOKKE**, AZ Turnhout, Turnhout, Belgium; **Martha KOPPELOW**, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; **Susanne KRASZ**, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; **Sabine KRAUSE**, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; **Sabine KRAUSPE**, Medizinische Klinik Fulda, Medizinische Klinik Fulda, Fulda, Germany; **Petra KWAKKENBOS**, Slotervaart ziekenhuis, Amsterdam, The Netherlands; **Nunzia LABARILE**, Policlinico di Bari, Università di Bari, Bari, Italy; **Hannah LANG**, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; **Marianne LASSAILLY**, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; **Martine LECONTE**, CHU Amiens, Université de Picardie Jules Verne, Amiens, France; **Linda LEP-CZYNSKI**, Universitätsmedizin Mannheim, Universitätsmedizin Mannheim, Mannheim, Germany; **Emma LEVELL**, Hampshire Hospitals, University of Southampton, Basingstoke, United Kingdom; **Nina LEVVAR**, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Kerstin LINDHORT**, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; **Jessica LISLE**, Hull University Teaching Hospitals, Hull York Medical School, University of Hull, Hull, United Kingdom; **Beatriz LOPEZ CAUCE**, Hospital Universitario Gregorio Marañón, Madrid, Spain; **Gabriele LORENZ**, Universitätsmedizin Mannheim, Universitätsmedizin Mannheim, Mannheim, Germany; **Ambr Lovati**, Ospedale Maggiore Policlinico di Milano, Università di Milano, Milano, Italy; **Tracey LOWRY**, Pinderfields Hospital, Wakefield, United Kingdom; **Margareta LUND**, Örebro University Hospital, Örebro, Sweden; **Anne LUTZ VORDERBRÜGGE**, Gastroenterologische Gemeinschaftspraxis Mainz, Mainz, Germany; **Suzanne MAANSSON**, North Zealand Hospital, University of Copenhagen, Hillerød, Denmark; **Videsheka MADAPATHAGE**, Hôpital de Meaux, Meaux, France; **Maelys CHEVIAKOFF**, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; **Alison MAGNESS**, Royal Shrewsbury Hospital, Keele University School of



Medicine, Staffordshire University, Shrewsbury, United Kingdom; **Orla MANLEY**, St Vincent University Hospital & University College Dublin, Dublin, Ireland; **Catherine MANYONI**, Torbay Hospital, Torquay, United Kingdom; **Ingke MARG**, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; **Antonella MARRA**, Policlinico di Bari, Università di Bari, Bari, Italy; **Carole MARTINS**, Hôpital Beaujon, Université de Paris, Cligny, France; **Arianna MASSELLA**, Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Italy; **Aurore MATHIAS**, CHU Bordeaux, Pessac, France; **Karin MENZEL**, MVZ Portal 10, Münster, Germany; **Danielle MERVYN**, St Vincent University Hospital & University College Dublin, Dublin, Ireland; **Charlotte MINSART**, Erasmus Hospital, VUB-ULB, Brussels, Belgium; **Sally MITCHELL**, Airedale General Hospital, Leeds University School of Medicine, Airedale, United Kingdom; **Kathleen MONKS**, Royal Liverpool University Hospital, University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; **Mélanie MONTERO**, CHRU Nancy, Université de Nancy, Nancy, France; **Alison MOORE**, Leicester Royal Infirmary, Leicester University, Leicester, United Kingdom; **Maren MOSER**, Competence Network for Intestinal Diseases e.V., Kiel, Germany; **Alison MOSS**, Musgrove Park Hospital, Taunton, United Kingdom; **Angela MULLEN**, MMUH, UCD, Dublin, Ireland; **M. Francisca MURCIANO**, Hospital del Mar, Barcelona, Autonomous University of Barcelona, Barcelona, Spain; **Deanna NAYLOR**, Colchester General Hospital, Barts and The London School of Medicine and Dentistry, Norwich Medical School, Anglia Ruskin University, Colchester, United Kingdom; **Ansgar NEHUS**, Praxis für Innere Medizin, Münster, Germany; **Anne NICHOLSON**, Basildon and Thurrock University Hospitals NHS Trust, Basildon, United Kingdom; **Sarah NÖDING**, Agaplesion Krankenhaus Frankfurt, Agaplesion Krankenhaus Frankfurt, Frankfurt, Germany; **Sinead NOLAN**, Bon Secours, UCC, Cork, Cork; **Janet NÖRENBERG**, Medizinische Klinik Fulda, Medizinische Klinik Fulda, Fulda, Germany; **Clare NORTHCOTT**, NHS Plymouth, Plymouth, United Kingdom; **Pauline OATES**, Sunderland Royal Hospital, Sunderland, United Kingdom; **Jim O'CONNELL**, St. James's Hospital, Dublin, Ireland; **Alison O'KELLY**, Colchester General Hospital, Barts and The London School of Medicine and Dentistry, Norwich Medical School, Anglia Ruskin University, Colchester, United Kingdom; **Noam ORBACH-ZINGBOIM**, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Judit OROBITG**, Hospital Universitari de Bellvitge, Universitat de Barcelona, Barcelona, Spain; **Charlene OTIENO**, Royal Derby Hospitals, Derby, United Kingdom; **Charlotte OWEN**, Royal Shrewsbury Hospital, Keele University School of Medicine, Staffordshire University, Shrewsbury, United Kingdom; **Sarah PATCH**, Poole Hospital, Poole, United Kingdom; **Maor PAUKER**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Renate PAULI**, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; **Harriet PEARSON**, York Hospital, Hull York Medical School, York, United Kingdom; **Falgon PEGGY**, Hôpital Lyon-Sud, Université Lyon 1, Lyon, France; **Séverine PETIT**, CHRU Nancy, Université de Nancy, Nancy, France; **Christine PETRISSANS**, Centre Hospitalier de la Côte Basque, Bayonne, France; **Simona PIERGALLINI**, Ospedale civile Augusto Murri, Fermo, Italy; **Lucy PIPPARD**, Yeovil District Hospital, Yeovil, United Kingdom; **Laura PITT**, York Hospital, Hull York Medical School, York, United Kingdom; **Gabriella PÓCSIK**, Albert Szent-Györgyi Health Center, University of Szeged, Szeged, Hungary; **Yoann POHER**, Nord Marseille, Université d'Aix-Marseille, Marseille, France; **Chloé POMES**, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; **Lucy PRITCHARD**, NHS Plymouth, Plymouth, United Kingdom; **Laura PUCHADES**, Hospital Clínico Universitario de Valencia, University of Valencia, Valencia, Spain; **Sheena QUAID**, Ealing Hospital, Imperial College London, London, United Kingdom; **Aleem RANA**, St George's Hospital, University of London, London, United Kingdom; **Aleem RANA**, St George's Hospital, University of London, London, United Kingdom; **Dana RAYNARD**, Worthing Hospital, Worthing, United Kingdom; **Mykila REILLY**, Stepping Hill Hospital, Stockport, United Kingdom; **Sonja REINERT**, Klinikum Lüneburg, Klinikum Lüneburg, Lüneburg, Germany; **Manuela REINKNECHT**, Gastroenterologische Facharztpraxis, Kassel, Germany; **Baerbel RENNER**, Universitätsklinikum Schleswig-Holstein, United KingdomSH Kiel, Kiel, Germany; **Rob REYNOLDS**, TUH, TCD, Dublin, Dublin; **Giulia RIZZUTO**, Ospedale V. Cervello, Palermo University, Palermo, Italy; **Matthew ROBINSON**, Calderdale Royal Hospital, Halifax, United Kingdom; **Joke ROBRECHTS**, Imelda Hospital, Bonheiden, Belgium; **Eva M. RODRIGUEZ**, Hospital Universitario de La Princesa, GETECCU (Grupo Español de Trabajo En enfermedad de Crohn y Colitis Ulcerosa) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Autonomous University of Madrid (UAM), Madrid, Spain; **Efrat ROSENBLUM**, Haemeq Medical Center, Faculty of Medicine Technion, Afula, Israel; **Tamiyl RUSSEL**, Musgrove Park Hospital, Taunton, United Kingdom; **Ibiyemi SADARE**, NHS Plymouth, Plymouth, United Kingdom; **Noa SALAMA**, Sheba Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Toos SCHA-KEL**, OLVG oost, Amsterdam, The Netherlands; **Anja SCHAUER**, Medizinische Klinik Fulda, Medizinische Klinik Fulda, Fulda, Germany; **Elisa SCHIAVONI**, Policlinico A. Gemelli, Fondazione Policlinico Universitario Gemelli, Roma, Italy; **Caroline SHAW**, Connolly Hospital, RCSI, Dublin, Ireland; **Sarah SHELTON**, King's Mill Hospital, University of Nottingham, Sutton-in-Ashfield, United Kingdom; **Virginie SICART**, Hôpital Rangueil, Université Toulouse 3, Toulouse, France; **Elodie SIOUVILLE**, CHU Nantes, Université de Nantes, Nantes, France; **Orla SMITH**, St Vincent University Hospital & University College Dublin, Dublin, Ireland; **Théo SOUDE**, CHU Nantes, Université de Nantes, Nantes, France; **Sophie STEPHENSON**, Bradford Teaching Hospitals, Leeds School of Medicine, Bradford, United Kingdom; **Elaine**

**STEPHENSON**, Royal Victoria Infirmary, Newcastle University Medical School, Newcastle, United Kingdom; **Marjan STEPPE**, BIRD GROUP, Landegem, Belgium; **An STERKX**, OLV-Aalst, Aalst, Belgium; **Jo STICKLEY**, Royal Shrewsbury Hospital, Keele University School of Medicine, Staffordshire University, Shrewsbury, United Kingdom; **Kathleen SUGRUE**, Mercy University Hospital, UCC, Cork, Ireland; **Natalia SWIETEC**, UZ Ghent, Ghent University, Ghent, Belgium; **Charlotte TASIAUX**, CHU Namur, site Godinne, University of Namur, Namur, Belgium; **Bhavneet THAMU**, Royal Hallamshire Hospital, University of Sheffield, Sheffield, United Kingdom; **Susane THOMAS**, Universitätsklinikum Carl Gustav Carus, University Hospital Carl Gustav Carus, Dresden, Germany; **Ogwa TOBI**, Watford General Hospital, Watford, United Kingdom; **Kahina TOUABI**, CHRU Nancy, Université de Nancy, Nancy, France; **Shifra TOVI**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Julie TREGONNING**, James Cook University Hospital, Durham University, Newcastle University, Middlesbrough, United Kingdom; **Laura TURCHINI**, Policlinico A. Gemelli, Fondazione Policlinico Universitario Gemelli, Roma, Italy; **Julia UNKHOF**, Gastroenterologische Gemeinschaftspraxis Münster, Münster, Germany; **Olesya UNRUH**, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; **Nurcan UZUN**, Charité Campus Benjamin Franklin, Charité Berlin, Berlin, Germany; **Frauke VAN AERT**, UZA, Antwerp University, Antwerp, Belgium; **Sandrine VANDEN BERGH**, Chwapi, Tournai, Belgium; **Louise VANDENBROUCKE**, AZ Damaia, Ostend, Belgium; **Laura VAN-STEENKISTE**, BIRD GROUP, Landegem, Belgium; **Shay VARDIT**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Valentin VERGRIETE**, CH Dunkerque, Dunkerque, France; **Elaine WALKER**, Watford General Hospital, Watford, United Kingdom; **Eleanor WARNER**, Maidstone Hospital, Maidstone, United Kingdom; **Olivia WATCHORN**, Leicester Royal Infirmary, Leicester University, Leicester, United Kingdom; **Ekaterina WATSON**, Ealing Hospital, Imperial College London, London, United Kingdom; **Marie-Claire WAUTHIER**, CHU St-Pierre, VUB-ULB, Brussels, Belgium; **Maria WEETMAN**, University Hospital of North Tees, Stockton, United Kingdom; **Margaret WESTON**, Leicester Royal Infirmary, Leicester University, Leicester, United Kingdom; **Wiebke WEST-PETROSCHKA**, Universitätsklinikum Schleswig-Holstein, United KingdomSH Kiel, Kiel, Germany; **Susann WIENECKE**, Klinikum Lüneburg, Klinikum Lüneburg, Lüneburg, Germany; **Kerstin WIERLING**, Gastroenterologische Gemeinschaftspraxis Münster, Münster, Germany; **Miriam WIESTLER**, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; **Rebecca WILCOX**, Royal Shrewsbury Hospital, Keele University School of Medicine, Staffordshire University, Shrewsbury, United Kingdom; **Elva WILHELMSEN**, James Paget University Hospital, University of Suffolk, Great Yarmouth, United Kingdom; **Angharad WILLIAMS**, West Suffolk Hospital, University of Suffolk, Suffolk, United Kingdom; **Georgina WILLIAMSON**, Wythenshawe Hospital, University of Manchester, Manchester, United Kingdom; **Deborah WILSON**, University Hospital of North Tees, Stockton, United Kingdom; **Kate WISTANCE**, Royal Shrewsbury Hospital, Keele University School of Medicine, Staffordshire University, Shrewsbury, United Kingdom; **Nicolas WORTMANN**, Medizinische Hochschule Hannover, Medizinische Hochschule Hannover, Hannover, Germany; **Subie WURIE**, University Hospital Coventry, University of Warwick, Coventry, United Kingdom; **Karin YADGAR**, Rabin Medical Center, Sackler Medical School Tel Aviv University, Ramat Gan, Israel; **Gail YOUNG**, Ulster Hospital, Belfast, United Kingdom; **Megan YOUNG**, Macclesfield District General Hospital, Macclesfield, United Kingdom.

**GETAID Contributors:** Julien AUCOUTURIER; Marie-Jo BERTIN; Hasnae BOUGRINE; Marie COISON; Antoine DEFRANCE; Kati GUTIERREZ; Amel HAROUZ; Laure JERBER; Aida KHLIFI; Amina KIRATI; Nasaladjine LIWORO; Maude LOGOLTAT; Charlotte MAILLAT; Chancelly M'BAYI; Yasmina MEDANE; Dalal MERKHOUFFA; Saouda MOHAMED ELHAD; Bertille MONTHE; Fanny MOYON; Pascaline RABIEGA; Jennifer SEKLA; Charlotte THILLOY.

**SANOIA Contributors (Digital interaction with patient):** Naima HAMA-MOUCHE, Frederic PARTISOTTI.

**CleanWeb Contributors (eCRF):** Patrick BLANDIN; Hocine MOKHTARI; Laure COUTARD.

#### CRedit Authorship Contributions:

Laurent Peyrin-Biroulet, MD, PhD (Conceptualization: Lead; Data curation: Equal; Investigation: Equal; Methodology: Equal; Project administration: Equal; Supervision: Lead; Validation: Lead; Visualization: Lead; Writing – original draft: Lead)

Jean-Francois Rahier (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)

Julien Kirchgessner (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)

Vered Abitbol (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)

Sebastian Shaji (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)

Alessandro Armuzzi (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Konstantinos Karmiris (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Javier P. Gisbert (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Peter Bossuyt (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Ulf Helwig (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Johan Burisch (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Henit Yanai (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Glen A. Doherty (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Fernando Magro (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Tamás Molnar (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Mark Lowenberg (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Jonas Halfvarson (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Edyta Zagorowicz (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Hélène Rousseau (Formal analysis: Equal; Methodology: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Cédric Baumann (Formal analysis: Equal; Methodology: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Filip Baert (Data curation: Equal; Investigation: Equal; Validation: Equal; Writing – review & editing: Equal)  
 Laurent Beaugerie (Conceptualization: Lead; Data curation: Equal; Investigation: Equal; Methodology: Equal; Project administration: Equal; Supervision: Lead; Validation: Lead; Visualization: Lead; Writing – review & editing: Lead)

#### Conflicts of Interest

These authors disclose the following: Laurent Peyrin-Biroulet has received personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boehringer Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Inotrem, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine, Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Entera, Theravance, and Pandion Therapeutics; has received grants from AbbVie, MSD, Takeda, and Fresenius Kabi; and owns stock options in CTMA. Rahier Jean-François has received speaker fees from AbbVie, MSD, Takeda, Pfizer, Ferring, Falk, Biogen, Amgen, and Celltrion; served as a consultant for AbbVie, Takeda, Hospira, Mundipharma, MSD, Pfizer, GlaxoSK, Janssen, and Celltrion; and received research grants from Takeda and AbbVie. Julien Kirchgesser has received consulting fees from Roche, Pfizer, and Gilead; and received research support from AbbVie. Vered Abitbol has received speaker fees from Takeda, Amgen, Mylan Viatrix, Sandoz, Janssen, Fresenius, Gilead, Tillotts, Galapagos, and Pfizer; and served as a consultant for Celltrion, Takeda, Amgen, Mylan Viatrix, Sandoz, Janssen, Fresenius, Gilead, Tillotts Pharma, Galapagos, and Pfizer. Sebastian Shaji has received research grants from Biogen, Takeda, AbbVie, Tillotts Pharma, Ferring, and Biohit; and served on the advisory board for Takeda, AbbVie, Merck, Ferring, Pharmacosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Celgene, and Tillotts Pharma; and received speaker fees from AbbVie, Biogen, AbbVie, Janssen, Merck, Warner Chilcott, and Falk Pharma. Alessandro Armuzzi has received consulting fees from AbbVie, Allergan, Amgen, Arena, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist, Roche, Samsung Bioepis, Sandoz, and Takeda; lecture fees from AbbVie, Amgen, Arena, Biogen, Bristol-Myers Squibb, Eli Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, and Tigenix; and research grants from


MSD, Takeda, Pfizer, and Biogen. Konstantinos Karmiris has received personal fees from AbbVie, Amgen, Enorasis, Ferring, Galenica, Genesis, Janssen, MSD, Pfizer, Takeda, and Vianex. Javier P. Gisbert has served as a speaker, a consultant, and on the advisory board for or received research funding from MSD, AbbVie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine, and Vifor Pharma. Peter Bossuyt has received financial support for research from AbbVie, Amgen, Celltrion, Mylan, Pfizer, and Takeda; lecture fees from AbbVie, Celltrion, Janssen, Lilly, and Takeda; and advisory board fees from AbbVie, Arena Pharmaceuticals, BMS, Celltrion, Dr. Falk, Galapagos, Janssen, Lilly, Pentax, PSI-CRO, Roche, Takeda, and Tetrameros. Ulf Helwig has received lecture/advisory board honoraria from MSD; AbbVie, Falk Foundation, Takeda, Mundipharma, Hospira, Ferring, Vifor, Mylan, Janssen, Pfizer, Celltrion, Galapagos, BMS, and Fresenius. Johan Burisch has served as a speaker, a consultant, and on the advisory board for or received research funding from MSD, AbbVie, Pfizer, Takeda, Janssen, Celgene, Bristol Myers Squibb, Galapagos, Ferring, Tillotts Pharma, Pharmacosmos, Vifor Pharma, and Novo Nordisk. Henit Yanai has received institutional research grants from Pfizer; consulting fees from AbbVie, Ferring, Janssen, Neopharm, Pfizer, and Takeda; received honoraria for lectures from AbbVie, Janssen, Pfizer, and Takeda; and served on the Data Safety Monitoring Board or advisory board for AbbVie, Neopharm, Pfizer, Takeda. Glen Doherty has received research grants/unrestricted educational grants from AbbVie, MSD, Pfizer, Janssen, Takeda, Tillotts, Amgen, Falk, Celltrion, Genuity Ireland, and Abbott; and fees for speaking, consulting, or advisory board service from AbbVie, MSD, Pfizer, Janssen, Takeda/Shire, Tillotts, Falk, Amgen, Mylan, Celltrion, Gilead, Galapagos, BMS, and Olympus. Fernando Magro has served as a speaker, a consultant, and on the advisory board for or received research funding from MSD, AbbVie, Pfizer, Biogen, Takeda, Janssen, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Otsuka Pharmaceutical, and Vifor Pharma. Tamás Molnar has served as a speaker and/or on the advisory board for AbbVie, Bristol Myers Squibb, Celgene, Dr. Falk, Egis, Ferring Pharmaceuticals, Fresenius Kabi, Janssen-Cilag, MSD, Mundipharma, Nutricia, Pfizer, Phytotec, Takeda, Teva, Sandoz, and Vifor Pharma; and received research grants from AbbVie, Pfizer, Takeda, and Vifor Pharma. Mark Lowenberg has served as speaker and/or principal investigator for AbbVie, Alimentiv, Bristol Myers Squibb, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Galapagos, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist Therapeutics, Receptos, Takeda, Tillotts, and Tramedico; and received research grants from AbbVie, Merck Sharp & Dohme, Dr. Falk, Achmea Healthcare, Galapagos, and ZonMw. Jonas Halfvarson has received personal fees for serving as a speaker, a consultant, and/or on the advisory board for AbbVie, Aqilion AB, Celgene, Celltrion, Dr. Falk Pharma and the Falk Foundation, Ferring, Galapagos, Gilead, Hospira, Index Pharma, Janssen, MEDA, Medivir, MSD, Novartis, Olink Proteomics, Pfizer, Prometheus Laboratories, Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, and UCB; and received grant support from Janssen, MSD, and Takeda, outside of the submitted work. Edyta Zagorowicz has received speaker fees from Janssen, Sandoz, Pfizer, and Takeda; and consulting fees from Takeda, Janssen, Sandoz, Ferring, and BMS. édicric Baumann has received speaker fees from Takeda. Filip Baert has served as a consultant and/or speaker for AbbVie, Arena, Celltrion, Falk, Ferring, Janssen, Mundipharma, MSD, Pfizer, Sandoz, Takeda, Vifor; and received research grants from AbbVie, Amgen, Chiesi, Ipsen, Janssen, and MSD. Laurent Beaugerie has received consulting fees from BMS, Janssen, Nordic Pharma, and Mylan; lecture fees from AbbVie, BMS, Janssen, MSD, Ferring, and Takeda; and research support from AbbVie, Celltrion, Ferring Pharmaceuticals, Hospira-Pfizer, Janssen, MSD, Mylan, Takeda, and Tillotts. The remaining author discloses no conflicts.

#### Funding

This work was supported by following partners: AbbVie, Amgen, Ferring, Pfizer, Janssen, MSD, and Takeda.

March 2023

Safety and Effectiveness of Biologics in IBD 788.e1




Presented here at the end of the study

### B I-CARE Contributors

<p><b>I-CARE EXECUTIVE COMMITTEE</b></p> <ul style="list-style-type: none"> <li>Filip BAERT (BE)</li> <li>Laurent BEAUGERIE (FR)</li> <li>Laurent PEYRIN-BIROULET (FR)</li> <li>Jean-François RAHIER (BE)</li> </ul>	<p><b>I-CARE CODING GROUP</b></p> <ul style="list-style-type: none"> <li>Julien KIRCHGESNER (coder referent)</li> <li>Daniel BERGEMALM (SE)</li> <li>Fiorella CANETE PIZARRO (ES)</li> <li>Benedicte CARON (FR)</li> <li>Kelly CHATTEN (UK)</li> <li>Rachel COONEY (UK)</li> <li>Marta COSSIGNANI (IT)</li> <li>Sandra DIAS (PT)</li> <li>Kludia FARKAS (HU)</li> <li>Klaudia GOREN (IL)</li> <li>Idan GOREN (IL)</li> <li>Tom HOLVOET (BE / NL)</li> <li>Taria IGBAL (UK)</li> <li>Susanne KRASZ (DE)</li> <li>Jimmy LIMDI (UK)</li> <li>Peter RIMMER (UK)</li> <li>Juliette SHERIDAN (IE)</li> <li>Mathieu UZZAN (FR)</li> <li>Nikos VIAZIS (GR)</li> <li>Petra WEIMERS (DK)</li> <li>Edyta ZAGOROWICZ (PL)</li> </ul>	<p><b>I-CARE NATIONAL COORDINATOR GROUP</b></p> <ul style="list-style-type: none"> <li>Vered ABITBOL (FR)</li> <li>Alessandro ARMUZZI (IT)</li> <li>Ann-Sofie BECKMAN (SE)</li> <li>Livia BIANCONE (IT)</li> <li>Peter BOSSUYT (BE)</li> <li>Johan BURISCH (DK)</li> <li>Glen DOHERTY (IE)</li> <li>Eugeni DOMENECH (ES)</li> <li>Javier GISBERT (ES)</li> <li>Jonas HALVVARSON (SE)</li> <li>Ulf HELWIG (DE)</li> <li>Mette JULSGAARD (DK)</li> <li>Konstantinos KARMIRIS (GR)</li> <li>Jaroslav KIERKUS (PL)</li> <li>Uri KOPYLOV (IL)</li> <li>Mark LOWENBERG (NL)</li> <li>Christian MAASER (DE)</li> <li>Fernando MAGRO (PT)</li> <li>Tamás MOLNAR (HU)</li> <li>Bas OLDENBURG (NL)</li> <li>Catherine REENAERS (BE)</li> <li>Sebastian SHAJI (UK)</li> <li>Britta SIEGMUND (DE)</li> <li>Nikolaos VIAZIS (GR)</li> <li>Henit YANAI (IL)</li> <li>Edyta ZAGOROWICZ (PL)</li> </ul>	<p><b>I-CARE SCIENTIFIC COMMITTEE</b></p> <p><b>EXECUTIVE COMMITTEE MEMBERS</b></p> <ul style="list-style-type: none"> <li>Filip BAERT (BE)</li> <li>Laurent BEAUGERIE (FR)</li> <li>Laurent PEYRIN-BIROULET (FR)</li> <li>Jean-François RAHIER (BE)</li> </ul> <p><b>NATIONAL COORDINATOR GROUP</b></p> <ul style="list-style-type: none"> <li>Vered ABITBOL (FR)</li> <li>Alessandro ARMUZZI (IT)</li> <li>Ann-Sofie BECKMAN (SE)</li> <li>Livia BIANCONE (IT)</li> <li>Peter BOSSUYT (BE)</li> <li>Johan BURISCH (DK)</li> <li>Glen DOHERTY (IE)</li> <li>EUGENI DOMENECH (ES)</li> <li>JAVIER GISBERT (ES)</li> <li>Jonas HALVVARSON (SE)</li> <li>Ulf HELWIG (DE)</li> <li>Mette JULSGAARD (DK)</li> <li>Konstantinos KARMIRIS (GR)</li> <li>Jaroslav KIERKUS (PL)</li> <li>Uri KOPYLOV (IL)</li> <li>Mark LOWENBERG (NL)</li> <li>Christian MAASER (DE)</li> <li>Fernando MAGRO (PT)</li> <li>Tamás MOLNAR (HU)</li> <li>Stephane NAHDON (FR)</li> <li>Bas OLDENBURG (NL)</li> <li>Catherine REENAERS (BE)</li> <li>Sebastian SHAJI (UK)</li> <li>Britta SIEGMUND (DE)</li> <li>Nikolaos VIAZIS (GR)</li> <li>Henit YANAI (IL)</li> <li>Edyta ZAGOROWICZ (PL)</li> </ul> <p><b>GETAID</b></p> <ul style="list-style-type: none"> <li>Charlotte MAILHAT (Project Director)</li> <li>Morie COISNON (Project Manager)</li> </ul>	
<p><b>I-CARE OPERATIONAL TEAM GETAID (PARIS)</b></p> <ul style="list-style-type: none"> <li>Charlotte MAILHAT (Project Director)</li> <li>Morie COISNON (Project Manager)</li> <li>Kati GUTIEREZ (Pharmacovigilance Director)</li> <li>Hasnae BOUGRINE (Datamanager)</li> <li>Antoine DEFRANCE (CRA)</li> <li>Jennifer SEKELA (Study coordinator)</li> <li>Bertille MONTHÉ (Pharmacovigilant)</li> </ul>	<p><b>PATIENT PLATFORM E-HEALTH SERVICES SANOLIA (GEMENOS)</b></p> <ul style="list-style-type: none"> <li>Najma HAMAMOUCHE-SERVY</li> <li>Frederic PARTISOTTI</li> </ul>	<p><b>eCRF TENTELEMEDECINE TECHNOLOGIES-CLEANWEB (PARIS)</b></p> <ul style="list-style-type: none"> <li>Patrick BLANDIN</li> <li>Hocine MOKHTARI</li> <li>Laure COUTARD</li> </ul>	<p><b>I-CARE METHODOLOGICAL TEAM PARC (NANCY)</b></p> <ul style="list-style-type: none"> <li>Cécile DAUMANN (Methodologist)</li> <li>Hélène ROUSSEAU (Statistician)</li> </ul>	

Supplementary Figure 1. I-CARE: history, contributors and data flow.



Supplementary Figure 1. Continued

Supplementary Table 1. Family History of IBD or Cancer

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
Family history of IBD							.0263
No	8442	88.1	3382	89.0	5060	87.5	
Yes	1141	11.9	418	11.0	723	12.5	
Missing	623		237		386		
Family history of lymphoma, colorectal cancer, melanoma, breast cancer							.0201
No	8485	88.7	3333	87.7	5152	89.1	
Yes	1085	11.3	466	12.3	619	10.7	
Missing	636		238		398		

IBD, inflammatory bowel disease.

<sup>a</sup>Chi-square test.



March 2023

Safety and Effectiveness of Biologics in IBD 788.e3

Supplementary Table 2. Previous Surgeries

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
Previous surgery							<.0001
No	7473	73.2	3877	96.0	3596	58.3	
Yes	2733	26.8	160	4.0	2573	41.7	
Proximal small bowel resection							<.0001
No	10,004	98.0	4036	100.0	5968	96.7	
Yes	202	2.0	1	0.0	201	3.3	
Ileocecal or ileal resection							<.0001
No	8699	85.2	4034	99.9	4665	75.6	
Yes	1507	14.8	3	0.1	1504	24.4	
Strictureplasty							<.0001
No	10,082	98.8	4036	100.0	6046	98.0	
Yes	124	1.2	1	0.0	123	2.0	
Segmental colectomy							<.0001
No	9855	96.6	4025	99.7	5830	94.5	
Yes	351	3.4	12	0.3	339	5.5	
Subtotal colectomy with ileorectal anastomosis							<.0001
No	10,039	98.4	4015	99.5	6024	97.6	
Yes	167	1.6	22	0.5	145	2.4	
Total proctocolectomy with ileoanal anastomosis							.7557
No	10,119	99.1	4004	99.2	6115	99.1	
Yes	87	0.9	33	0.8	54	0.9	
Surgical drainage of abdominal abscess							<.0001
No	10,038	98.4	4028	99.8	6010	97.4	
Yes	168	1.6	9	0.2	159	2.6	
Permanent stoma							<.0001
No	10,085	98.8	4036	100.0	6049	98.1	
Yes	121	1.2	1	0.0	120	1.9	
Perianal surgery							<.0001
No	9345	91.6	3982	98.6	5363	86.9	
Yes	861	8.4	55	1.4	806	13.1	

IBD, inflammatory bowel disease.

<sup>a</sup>Chi-square test.

**Supplementary Table 3.** Previous 5-ASA and Corticosteroid Treatments

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
<b>Any oral form of 5-ASA</b>							<.0001
No	5967	63.6	2679	72.2	3288	58.0	
Yes	3413	36.4	1034	27.8	2379	42.0	
Missing	826		324		502		
<b>Foam, suppositories, or enema form of 5-ASA</b>							<.0001
No	7223	76.4	2086	55.5	5137	90.2	
Yes	2229	23.6	1670	44.5	559	9.8	
Missing	754		281		473		
<b>Any form of systemic corticosteroids</b>							.0063
No	3223	34.1	1344	35.7	1879	33.0	
Yes	6237	65.9	2420	64.3	3817	67.0	
Missing	746		273		473		
<b>Budesonide</b>							<.0001
No	7474	79.0	3496	92.8	3978	69.9	
Yes	1990	21.0	270	7.2	1720	30.1	
Missing	742		271		471		
<b>Budesonide MMX</b>							<.0001
No	9383	98.9	3701	98.2	5682	99.4	
Yes	106	1.1	69	1.8	37	0.6	
Missing	717		267		450		
<b>Beclometasone</b>							<.0001
No	9057	95.4	3425	90.9	5632	98.4	
Yes	434	4.6	344	9.1	90	1.6	
Missing	715		268		447		

5-ASA, mesalamine; IBD = inflammatory bowel disease.

<sup>a</sup>Chi-square test.

March 2023

Safety and Effectiveness of Biologics in IBD 788.e5

Supplementary Table 4. Previous Immunomodulator Treatments

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
<b>Azathioprine</b>							<.0001
No	7070	69.3	3161	78.3	3909	63.4	
Yes	3136	30.7	876	21.7	2260	36.6	
<b>Azathioprine: estimated duration of treatment before entry in I-CARE</b>							
<1 y	1488	48.4	473	55.1	1015	45.8	
1 y	302	9.8	76	8.8	226	10.2	
2 y	309	10.1	79	9.2	230	10.4	
3 y	182	5.9	45	5.2	137	6.2	
4 y	163	5.3	45	5.2	118	5.3	
5 y	128	4.2	34	4.0	94	4.2	
6 y	119	3.9	28	3.3	91	4.1	
7 y	81	2.6	25	2.9	56	2.5	
8 y	57	1.9	12	1.4	45	2.0	
9 y	42	1.4	5	0.6	37	1.7	
10 y	47	1.5	8	0.9	39	1.8	
11 y	37	1.2	9	1.0	28	1.3	
12 y	36	1.2	4	0.5	32	1.4	
13 y	23	0.7	5	0.6	18	0.8	
14 y	11	0.4	4	0.5	7	0.3	
15 y	9	0.3	1	0.1	8	0.4	
16 y	13	0.4	1	0.1	12	0.5	
17 y	9	0.3	0	0.0	9	0.4	
18 y	4	0.1	1	0.1	3	0.1	
20 y	5	0.2	1	0.1	4	0.2	
21 y	2	0.1	0	0.0	2	0.1	
22 y	1	0.0	1	0.1	0	0.0	
24 y	1	0.0	0	0.0	1	0.0	
25 y	1	0.0	1	0.1	0	0.0	
26 y	1	0.0	0	0.0	1	0.0	
29 y	1	0.0	0	0.0	1	0.0	
>30 y	1	0.0	1	0.1	0	0.0	
Missing	63		17		46		
<b>6-Mercaptopurine</b>							<.0001
No	9728	95.3	3890	96.4	5838	94.6	
Yes	478	4.7	147	3.6	331	5.4	
<b>6-Mercaptopurine: estimated duration of treatment before entry in I-CARE</b>							
<1 y	330	70.5	100	68.5	230	71.4	
1 y	44	9.4	15	10.3	29	9.0	
2 y	24	5.2	7	4.8	17	5.3	
3 y	20	4.3	4	2.7	16	5.0	
4 y	10	2.1	5	3.4	5	1.6	
5 y	6	1.3	3	2.1	3	0.9	
6 y	8	1.7	4	2.7	4	1.3	
7 y	6	1.3	3	2.1	3	0.9	
8 y	6	1.3	3	2.1	3	0.9	
9 y	4	0.9	1	0.7	3	0.9	
10 y	2	0.4	0	0.0	2	0.6	
11 y	2	0.4	1	0.7	1	0.3	
12 y	2	0.4	0	0.0	2	0.6	
14 y	1	0.2	0	0.0	1	0.3	
15 y	1	0.2	0	0.0	1	0.3	
16 y	1	0.2	0	0.0	1	0.3	
18 y	1	0.2	0	0.0	1	0.3	
Missing	10		1		9		
<b>Methotrexate</b>							<.0001
No	9568	93.7	3931	97.4	5637	91.4	
Yes	638	6.3	106	2.6	532	8.6	

Supplementary Table 4. Continued

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
Methotrexate: estimated duration of treatment before entry in I-CARE							
<1 y	316	51.2	59	57.8	257	49.9	
1 y	99	16.0	15	14.7	84	16.3	
2 y	86	13.9	14	13.7	72	14.0	
3 y	33	5.3	6	5.9	27	5.2	
4 y	28	4.5	4	3.9	24	4.7	
5 y	14	2.3	0	0.0	14	2.7	
6 y	13	2.1	0	0.0	13	2.5	
7 y	10	1.6	2	2.0	8	1.6	
8 y	7	1.1	0	0.0	7	1.4	
9 y	3	0.5	0	0.0	3	0.6	
10 y	5	0.8	1	1.0	4	0.8	
12 y	1	0.2	1	1.0	0	0.0	
14 y	1	0.2	0	0.0	1	0.2	
15 y	1	0.2	0	0.0	1	0.2	
Missing	21		4		17		

I-CARE, IBD Cancer and serious infections in Europe; IBD, inflammatory bowel disease.

<sup>a</sup>Chi-square test.



March 2023

Safety and Effectiveness of Biologics in IBD 788.e7

Supplementary Table 5. Previous Biological Treatments

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
<b>Infliximab</b>							<.0001
No	7790	82.2	3286	86.6	4504	79.2	
Yes	1690	17.8	507	13.4	1183	20.8	
Missing	726		244		482		
<b>Infliximab: estimated duration of treatment before entry in I-CARE</b>							
<1 y	743	44.8	249	49.8	494	42.6	
1 y	269	16.2	92	18.4	177	15.3	
2 y	247	14.9	62	12.4	185	15.9	
3 y	145	8.7	36	7.2	109	9.4	
4 y	93	5.6	25	5.0	68	5.9	
5 y	55	3.3	12	2.4	43	3.7	
6 y	27	1.6	8	1.6	19	1.6	
7 y	30	1.8	7	1.4	23	2.0	
8 y	11	0.7	2	0.4	9	0.8	
9 y	16	1.0	3	0.6	13	1.1	
10 y	7	0.4	2	0.4	5	0.4	
11 y	4	0.2	1	0.2	3	0.3	
12 y	5	0.3	0	0.0	5	0.4	
13 y	1	0.1	1	0.2	0	0.0	
14 y	2	0.1	0	0.0	2	0.2	
15 y	4	0.2	0	0.0	4	0.3	
17 y	1	0.1	0	0.0	1	0.1	
Missing	30		7		23		
<b>Adalimumab</b>							<.0001
No	8186	86.0	3515	92.3	4671	81.8	
Yes	1334	14.0	292	7.7	1042	18.2	
Missing	686		240		456		
<b>Adalimumab: estimated duration of treatment before entry in I-CARE</b>							
<1 y	562	42.9	184	64.1	378	36.9	
1 y	242	18.5	51	17.8	191	18.7	
2 y	185	14.1	27	9.1	158	15.4	
3 y	131	10.0	13	4.5	118	11.5	
4 y	71	5.4	7	2.4	64	6.3	
5 y	44	3.4	2	0.7	42	4.1	
6 y	36	2.7	0	0.0	36	3.5	
7 y	17	1.3	1	0.3	16	1.6	
8 y	10	0.8	0	0.0	10	1.0	
9 y	4	0.3	1	0.3	3	0.3	
10 y	6	0.5	1	0.3	5	0.5	
11 y	2	0.2	0	0.0	2	0.2	
17 y	1	0.1	0	0.0	1	0.1	
Missing	23		5		18		
<b>Certolizumab pegol</b>							<.0001
No	9501	99.4	3805	99.8	5696	99.1	
Yes	60	0.6	6	0.2	54	0.9	
Missing	645		226		446		
<b>Certolizumab: estimated duration of treatment before entry in I-CARE</b>							
<1 y	35	59.3	2	33.3	33	62.3	
1 y	14	23.7	2	33.3	12	22.6	
2 y	4	6.8	0	0.0	4	7.5	
3 y	4	6.8	1	16.7	3	5.7	
4 y	1	1.7	0	0.0	1	1.9	
5 y	1	1.7	1	16.7	0	0.0	
Missing	1		0		1		

Supplementary Table 5. Continued

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
<b>Golimumab</b>							<.0001
No	9347	98.5	3700	97.1	5717	99.4	
Yes	141	1.5	109	2.9	32	0.6	
Missing	648		228		420		
<b>Golimumab: estimated duration of treatment before entry in I-CARE</b>							
<1 y	95	68.8	74	67.9	21	72.4	
1 y	25	18.1	22	20.2	3	10.3	
2 y	11	8.0	9	8.3	2	6.9	
3 y	6	4.3	4	3.7	2	6.9	
4 y	1	0.7	0	0.0	1	3.4	
Missing	3		0		3		
<b>Vedolizumab</b>							.0030
No	9392	98.5	3753	98.9	5639	98.2	
Yes	147	1.5	41	1.1	106	1.8	
Missing	667		243		424		
<b>Vedolizumab: estimated duration of treatment before entry in I-CARE</b>							
<1 y	91	63.2	29	72.5	62	59.6	
1 y	32	22.2	6	15.0	26	25.0	
2 y	16	11.1	3	7.5	13	12.5	
3 y	4	2.8	2	5.0	2	1.9	
4 y	1	0.7	0	0.0	1	1.0	
Missing	2		1		1		
<b>Ustekinumab</b>							.0002
No	9518	99.6	3807	99.9	5711	99.4	
Yes	38	0.4	4	0.1	34	0.6	
Missing	650		226		424		
<b>Ustekinumab: estimated duration of treatment before entry in I-CARE</b>							
<1 y	28	73.7	3	75.0	25	73.5	
1 y	4	10.5	0	0.0	4	11.8	
2 y	2	5.3	1	25.0	1	2.9	
3 y	1	2.6	0	0.0	1	2.9	
4 y	3	7.9	0	0.0	3	8.8	

I-CARE, IBD Cancer and serious infections in Europe; IBD, inflammatory bowel disease.

<sup>a</sup>Chi-square test.

March 2023

Safety and Effectiveness of Biologics in IBD 788.e9

**Supplementary Table 6.** History of Cancer

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
Personal history of cancer							.0395
No	9908	97.1	3902	96.7	6006	97.4	
Yes	298	2.9	135	3.3	163	2.6	
Dysplasia colon							.1574
No	10,186	99.8	4026	99.7	6160	99.9	
Yes	20	0.2	11	0.3	9	0.1	
Dysplasia esophagus							.2827
No	10,203	100.0	4037	100.0	6166	100.0	
Yes	3	0.0	0	0.0	3	0.0	
Dysplasia uterine cervix (only CIN 3)							.1496
No	10,135	99.3	4003	99.2	6132	99.4	
Yes	71	0.7	34	0.8	37	0.6	
Dysplasia uterine cervix (only women)							.0756
No	5314	98.7	1998	98.3	3316	98.9	
Yes	71	1.3	34	1.7	37	1.1	

IBD, inflammatory bowel disease.

<sup>a</sup>Chi-square test or Fisher's exact test.

Supplementary Table 7. History of Vaccination and Infection

	Total (N = 10,206)		Ulcerative Colitis or IBD Unclassified (n = 4037 [39.6%])		Crohn's Disease (n = 6169 [60.4%])		P <sup>a</sup>
	n	%	n	%	n	%	
Human papillomavirus vaccine							.6856
No	6088	93.8	2443	94.0	3645	93.7	
Yes	404	6.2	158	6.0	246	6.3	
Missing	3714		1436		2278		
Hepatitis B vaccine							.0379
No	2646	43.5	1093	45.1	1553	42.4	
Yes	3441	56.5	1331	54.9	2110	57.6	
Missing	4119		1613		2506		
Pneumococcus vaccine							<.0001
No	4031	64.9	1762	71.6	2269	60.5	
Yes	2184	35.1	700	28.4	1484	39.5	
Missing	3991		1575		2416		
BCG vaccine							.4242
No	2609	46.1	1074	46.8	1535	45.7	
Yes	3046	53.9	1222	53.2	1824	54.3	
Missing	4551		1741		2810		
Herpes zoster							.7668
No	5984	97.4	2426	97.5	3558	97.3	
Yes	160	2.6	63	2.5	97	2.7	
Missing	4062		1548		2514		
Confirmed symptomatic mononucleosis							.2027
No	7178	95.0	2910	95.4	4268	94.8	
Yes	376	5.0	140	4.6	236	5.2	
Missing	2652		987		1665		

BCG, Bacille Calmette-Guérin; IBD, inflammatory bowel disease.

<sup>a</sup>Chi-square test.